Draft REACH (Amendment) Regulations 2023
Jo Churchill Excerpts(1 year, 7 months ago)
General CommitteesRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Rebecca Pow
I honestly do not believe that there is cause for concern. There might be divergence in terms of flexibility or decisions that might be made at slightly different times. She mentioned various substances. That is more a matter of timing and of when the announcements are made, but there will not be any divergence in the fundamental principles and guarantees that safety and protection of the environment and human health is paramount. That still stands and it will not change.
NGO stakeholders have also raised this issue and said that they want divergence to be kept to a minimum. The EU is also seeking to improve the quality of its information on use and exposure, so our work on the alternative model could serve to reduce the scope of the new divergence. Having our own independent regulatory framework for chemicals allows us to identify the most pressing priorities that best reflect our circumstances in GB. The decisions we take are based on the best available evidence, including looking at approaches taken by chemical regimes across the world, including the EU. The Health and Safety Executive already looks at other sources and will continue to do so, as I think I said in my opening speech.
The shadow Minister asked about the capacity of HSE. Its capacity is increasing all the time. The NAO’s report from May 2022 shows that it increased staffing in its chemicals regulation division by 46% between September 2020 and March 2022. It continues to build on that capacity. In the long term, by 2025 the number of HSE staff working on UK REACH delivery is expected to grow to 50, and the number is around 60 or 70 if we consider the wider support functions. Members might be interested if I break that down. There are currently about 15 toxicologists, with six established and nine promoted or early career scientists. In addition, HSE can call on REACH independent scientific experts—the pool members—and the expert scientists on a whole range of different committees, as well as the eco-toxicologists who work for the Environment Agency, to support its work. I hope that makes very clear that the capacity of HSE has been ramped up, and that it is working alongside the new requirements to get the system absolutely right.
To go back to chemicals and restrictions, a suggestion was made that potentially it is not safe here and we are not banning chemicals that have been banned elsewhere. That is categorically not the case. Work is well under way to address risky chemicals. Upcoming decisions include restrictions on lead in ammunition and on toxic substances in tattoo inks and permanent make-up. I do not know if you have a tattoo, Sir Graham.
Rebecca Pow
In April, HSE and the EA published a regulatory management options analysis on PFAS, or “forever chemicals”, and they will be considering the recommendations for restrictions on other regulatory measures. And we are banning PFAS in firefighting foams. I think the hon. Member for Newport West mentioned that, but that is one thing that we have announced. Under the UK REACH work programme, we will be working our way through a whole range of restrictions, obviously with all of the right evidence to inform decisions made.
Genetic Technology (Precision Breeding) Bill (Fifth sitting)
Jo Churchill Excerpts(2 years, 5 months ago)
Public Bill CommitteesRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Deidre Brock
Thank you for your guidance, Mr Davies. If the Opposition were to choose to press amendment 29 to a vote, I would support it. From the moment the Bill was published, the Scottish Government raised the issue as a direct threat to Scottish interests. The EU is not considering animals as part of its review, so the potential for the UK Government to align with our largest trading partner and its eventual position is even further reduced by this measure. I look forward very much to the Minister’s comments on those points and to the points I raise in the future.
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
It is a pleasure to serve under your chairmanship, Mr Davies. I thank the hon. Member for Cambridge for his opening statement, which highlighted that Labour is supportive of science and innovation, and of making sure that as a country we optimise those things in which we really do excel.
I acknowledge the support that the Bill has received from the research community, industry and a broad base of stakeholders. We heard in the evidence sessions how important and exciting this area is, and about the potential benefits for the food system and the environment. None the less, at the outset, I would like to state that I appreciate the concerns raised. I hope that the debates that follow and the way in which we proceed reassure the hon. Member and others. We intend to move slowly and steadily and to follow the science.
As explained on Second Reading, the Government believe that legislation has not kept pace with developments. The existing provision is some 30 years old, and our understanding of the safety and benefits of technology such as gene editing has advanced significantly. We have already taken that first step in regulatory reform with the statutory instrument that came into force in April. It has already enabled exciting research in the hon. Gentleman’s and my part of the world, East Anglia, into high vitamin D tomatoes, which could bring health benefits to many, although I appreciate the hon. Gentleman’s observation that even in that case we need to think carefully.
Deidre Brock
I appreciate the Minister’s enthusiasm and her ambitions for everything that the Bill might be able to achieve, but given that Europe is not looking at gene editing for animals as a part of its review—certainly not at the moment—how will that further affect our trade in animals with Europe, particularly if no labels or traceability are attached to these animals?
Jo Churchill
I believe that the hon. Lady has tabled amendments on that subject, and we will come on to discuss them. In my view, this is part of our responsibility, alongside that of the scientists, who are at the forefront of what they do. I would gently temper the hon. Lady’s description: this is not unbounded enthusiasm; it is pragmatism. It is about a deep belief in our science and our ability to do good; that is different from enthusiasm. We are building in transparency, and we need to utilise those skills. On my visits to these great institutes around the country, I have met scientists and researchers from across the world, not only Europe. Although I take the hon. Lady’s point about gravity economics, what we do has a broader benefit to people across the world. There are clear benefits.
We need to safeguard welfare, and that is why we have laid down in the Bill a framework for the regulatory system. It is imperative that we get this right. That is why it is important that we work with expert groups, industry and non-governmental organisations on enabling the right regulations to ensure that the system is effective, safe and workable.
All animals are protected by comprehensive and robust legislation, including the Animal Welfare Act 2006, which makes it an offence to cause any captive animal unnecessary suffering and to not provide for their welfare needs. The Bill’s system to protect animal health and welfare will work with those regulations. The Animal Welfare Act is supplemented by detailed regulations on farmed animal welfare. The Welfare of Farmed Animals (England) Regulations 2007 include specific requirements to protect animals that are bred or kept. The regulations prohibit breeding procedures that cause or are likely to cause suffering or injury. They state:
“Animals may only be kept for farming purposes if it can reasonably be expected, on the basis of their genotype or phenotype, that they can be kept without any detrimental effect on their health or welfare.”
In addition, animals used in scientific research projects, which would be the first stage of developing a breeding line using precision breeding for animals, are protected by the Animals (Scientific Procedures) Act 1986—ASPA—which was referred to in the evidence we took from the Royal Society for the Prevention of Cruelty to Animals, which was glad to see that that is the case. This legislation ensures that animals are only ever used in science where the potential harm to animals is limited, there are no alternatives, and where the number of animals is the minimum needed to achieve a scientific benefits, and that includes a harm-benefit analysis.
The measures we are introducing support the regulations by requiring an animal welfare declaration and independent scrutiny by an expert group before an animal can be marketed. We are ensuring that the health and welfare of the animal and its offspring will not be adversely affected by any trait resulting from precision breeding.
If we want to drive innovation and investment in this area while continuing to be at the forefront of animal welfare, we need to move forward and show how the best regulatory systems can work. The Bill provides a clear signal that the UK is the best place to conduct the research and bring products to market. I therefore urge the hon. Member for Cambridge to withdraw his amendment.
Daniel Zeichner
I thank the Minister for her constructive tone. I suspect that the arguments we will pursue over the next few days are already becoming clear. There is considerable agreement. No one disputes that it would be wonderful to be able to tackle bird flu or PRRS. Of course, if we can find a solution, it would be hugely beneficial not just in a financial sense but in terms of welfare as well. The question is how best to achieve that, and I suspect that that is going to be the key part of the debate.
I shall start by admitting my first procedural failure of the day. Contrary to my original suggestion, I am advised by the Clerks that we cannot yet vote on amendment 28 because it does not relate to this clause. Therefore, with your permission, Mr Davies, I would like to reverse my original suggestion and ask that we vote on amendment 29 but not on amendments 28 and 30. Despite spending many hours sitting on Bill Committees, some of us are still learning some of the procedures. I understand that amendment 28 relates to the long title of the Bill.
To go back to the broader issue, some of the points made by our SNP colleague, the hon. Member for Edinburgh North and Leith, will come back in our discussions, I am afraid, because where we sit in relation to other jurisdictions and approaches is a complicated question. There is no two ways about that, and I will say more about it in a few moments’ time.
The cost issue raised by the Minister—the £1.75 billion—was interesting. There are potentially huge benefits here, so it is odd, looking at the impact assessment, to see the relatively modest sums that the existing system puts in place. I wonder whether there is a slight mismatch in seeing the current set-up as such a brake on development; it seems to me that there may be other issues as well, although I might be missing something. We are trying to achieve the right regulatory framework to allow investment to take place; the question is whether this the right way to do it. At the moment, I persist in thinking that the measures before us on protection for animals are not sufficiently developed.
Something I have noticed in other Bill Committees I have been involved in is that we home in on the legislation before us and it is quite hard for Members to understand fully the wider landscape in which that legislation sits. It might be assumed that Members are all-knowing and fully understand the entire set-up, but to me, it sometimes feels more like looking at a lump of marble and trying to discern the sculpture within. We need to be pretty imaginative to see exactly where the Bill fits and what consequences it will have.
I am reassured on some of the points about the wider framework for animal protection, but it is also fair to say that there has been a lot of legislation recently. For this, the Government deserve some credit: it is changing the landscape, but it is not entirely clear how it will all fit together. That gives further weight to our view that, on balance, it would be better not to bring the provisions in this part of the Bill into force until further work has been done.
Question put, That the amendment be made.
Daniel Zeichner
I am grateful for the intervention—enthusiasm is welcome. The hon. Lady gets to the nub of the point: it is very difficult to describe in law—which is what we as legislators are trying to do—the complexities of the natural world. I suspect that we will probably go around in circles on this, but my point is that the reliance on the notion of something occurring naturally would make the law difficult to interpret—that is key. That is why it is hard for legislators to pin those things down, and I have some sympathy with who have had to capture them in drafting the Bill.
As I am sure the Committee will remember, I pressed Professor Henderson on that point. He said:
“The Bill is designed not to allow exogenous material”.
That is not explicitly coded in the Bill, however. He also said that this is
“something of a grey area.”––[Official Report, Genetic Technology (Precision Breeding) Public Bill Committee, 28 June 2022; c. 15, Q18.]
He was absolutely right about that. He said that transgenesis can occur naturally, and he drew a distinction between intentional and unintentional transfer, which, again, I can understand.
I appreciate that, as the hon. Member for South Ribble implied, the distinction is complicated and messy, but it is important. Unfortunately, although that is the distinction that the Government have presented in the Bill, not only does it not appear in the Bill, but it is contradictory. As we read it, it seems that transgenesis is possible under the Bill, so long as it could have occurred naturally or through traditional breeding processes. I appreciate that it is difficult, but I ask the Minister to explain today how her earlier remarks, and the remarks made by others—that gene editing does not involve introducing DNA from one organism into another—are reflected in the Bill. I do not think they are.
The other related point is the general looseness of the definitions in the Bill. I am sure we all recall the striking evidence from Dr Edenborough QC, a distinguished lawyer, who may well end up advising on how disputes in this area might be resolved. That is an important point: we are setting the law, but others will then interpret it. If it is not clear, we will see trouble ahead.
As Dr Edenborough explained in the evidence session,
“‘could have resulted from’ is staggeringly imprecise. Is that ‘likely’? Is that ‘very possible’? What level of probability is it?”—Official Report, Genetic Technology (Precision Breeding) Public Bill Committee, 30 June 2022; c. 125, Q199.]
In essence, he raised that many things that would be permissible under the Bill and qualify as precision bred organisms would be unclear. The Government need to clarify what they intend here. Without clarity, there is a real risk of challenge. That goes back to my opening point, and I think it will be a thread running through our debates. With the lack of clarity comes uncertainty, and with uncertainty comes a risk to investment, which is exactly opposite to what the Bill is designed to achieve.
That is why we have tabled the amendments—to try to bring the Bill in line with the distinctions the Government have themselves drawn between genetic editing and genetic modification. The amendments would tighten up the Bill, provide clarity of purpose and bring the Bill in line with the Government’s stated aims.
Amendment 1 explicitly rules out transgenesis by adding a new subsection to clause 1, while amendment 2 amends the definition in the subsection (8) definition of “modern biotechnology” to exclude the introduction of “exogenous genetic material”. Both amendments would bring the Bill into line with the stated objectives of the Government. We will seek a division on amendment 1, although I am happy to withdraw amendment 2. We hope the Government can support us on amendment 1.
Jo Churchill
Amendment 1 would exclude from the definition of a precision bred organism any organism that has contained transgenic material during any step of its development. I thank the hon. Member for the amendment, but do not feel that it follows the best scientific advice and evidence and would undermine the purpose of the Bill.
It is important that we follow scientific advice and regulate based on the nature of genetic changes made to organisms, rather than on techniques used to develop them. The scientific advice is clear: if an organism contains genetic changes that could have occurred naturally or by traditional breeding methods, that does not present a greater risk than a traditionally bred counterpart, irrespective of the techniques used to develop it.
No precision bred organism will contain transgenes. Some of its ancestors may have contained them, but those transgenes must have been removed for the organism to be classified as precision bred. That is laid out in the Bill.
The transgenic intermediate stages are important, as they enable the precise changes to be made to the DNA of organisms. The transgenes themselves are then subsequently removed. For example, CRISPR-Cas9 DNA would need to be taken out of precision bred animals and plants.
During the evidence sessions, we heard from Professor Nigel Halford of Rothamsted Research. He is using that approach to develop low-acrylamide wheat—a wheat that can provide public health benefits, as well as broader benefits.
Kate Green (Stretford and Urmston) (Lab)
I apologise to the Committee for displaying my ignorance, but I am interested in the Minister’s comments about the potential ancestry of genes’ genetic material, which would then have been removed by the end of process. Does that happen in nature?
Jo Churchill
It has to go through the regulatory framework to be defined as precision bred, to ensure that any of those precise changes are changes that could have occurred in nature, because we are describing what would happen in nature.
Katherine Fletcher
In nature there will be random deletions continually within the genome, so the idea of sections of DNA being taken out or added in is part of the process.
Kate Green
Is the Minister therefore saying that it is not possible to determine whether the way in which genetic material may have moved in and out will replicate what could have happened in nature, but only that the outcome will replicate what could have happened in nature?
Jo Churchill
During the evidence sessions, we heard from Professor Halford and Professor John Napier, who is developing camelina crops that are high in healthy oils. In both examples that they cited, transgenic DNA introduced during the gene editing process was removed. Under the amendment, both of those examples would fall outside the scope of the Bill, and the plants would be classed as genetically modified organisms, but they are not, because they do not contain any transgenes that are actually part of the process The hon. Member for Cambridge referred to the fact that we can have these little bits of DNA left over in ourselves from viruses and so forth.
We must make sure that we understand what we are looking at. We heard very clearly from Professors Halford and Napier that the techniques are more targeted and therefore very precise, known changes can be made. Therefore we know what we are looking at, and this is stepwise procedure. Some of the narrative infers that the Bill will be passed, and then, tomorrow, the changes will happen. It is not like that; we are talking about the development of science and ensuring that the regulatory framework that we have been working under from 30 years ago, which has been recognised virtually across the world as inadequate, is changed, so that we can keep up with the science.
If we accepted the amendment, it would make the Bill irrelevant. Countries elsewhere with proportionate regulations would be able to exploit the huge potential of the technology as it develops, whereas we would remain impeded by the current legislation. I urge hon. Member for Cambridge to withdraw the amendment relating to the definition of precision bred organisms, although I think he said that he intended to push it to a vote.
Jo Churchill
Yes.
The hon. Gentleman has said that he will not push amendment 2 to a vote. The amendment focuses on the definition of modern biotechnology. The techniques to which he refers were the subject of the European Court of Justice case in 2018, to which he also referred. That finding set us on today’s path. The Court ruled that all organisms produced by the techniques should be regulated as genetically modified organisms, irrespective of whether the end product could have occurred naturally or by traditional breeding.
As we heard from Sam Brooke of the British Society of Plant Breeders in the first evidence session, that ruling resulted in many companies halting their research on gene editing and other precision breeding techniques. Subsequently, the EU has recognised that that finding is not in line with current scientific knowledge or development, and has committed to reviewing its own legislation. That is why I am keen that we share our knowledge with it to help us all move forward.
Under the Bill as currently drafted, organisms produced by the techniques should only be classed as GMOs if the genetic changes they contain could not have occurred naturally, or been produced by traditional breeding methods. That does not mean that we consider that the exogenous DNA must be excluded from the process of producing such organisms altogether, as stated. The key point is that we should focus on the nature of the genetic changes in organisms, which are actually released or marketed, as per the scientific advice from the Advisory Committee on Releases to the Environment. The broad guidance it produces is very clear. It means that, in order to produce a precision bred organism, developers have to remove exogenous DNA, such as the CRISPR-Cas9 gene used in gene editing, from the organisms. In effect, they are removing the tool they used to make the changes, leaving behind the new trait.
In order to carve out precision bred organisms from the legislation controlling the use of GMOs with the Bill, we have defined the techniques used to produce them as “modern biotechnology”. We are then separating organisms produced by modern biotechnology into GMOs and precision bred organisms in order to ensure that the two regulatory systems dovetail. That term must remain aligned to the GMO legislation, which means continuing to include techniques that introduce exogenous DNA. I am therefore grateful to the hon. Gentleman for withdrawing amendment 2.
Daniel Zeichner
I apologise to Members for detaining them, but I want to speak to the clause because it is a key part of the Bill. We are at this point establishing a new category of a precision bred organism. My worry is that it is not a clear category, not least because only a few months ago another new category was introduced—the higher qualifying plant. The Genetically Modified Organisms (Deliberate Release) (Amendment) (England) Regulations 2022 were discussed in this very Committee room—I remember the Minister and I discussing them—and have come into force, which was an initial step before this Bill was introduced. At the time, I highlighted the warnings from various learned societies that that was not a category that they recognised, and I am afraid the precision bred organism occupies a similarly ill-defined space.
In the Bill, reference is made to other previous SIs, but not to the most recent one. I notice that the SI from 2002 is referenced in subsection 3, where “modern biotechnologies” are defined, but I cannot see any reference to this year’s SI, so perhaps the Minister will tell us what is happening with that. Paragraph 3.2.2.1 of the impact statement makes it clear that the intention is to revoke the SI and reintroduce the provisions in the Bill, but it certainly is not clear to me where in the Bill that is being done, so I hope the Minister will elucidate. Perhaps it is hidden in the secondary legislation provisions, in which case it is quite opaque, which is part of our general concern about the Bill.
The danger is that we could be in a position where we unintentionally have two pieces of law governing this area and laying out two different definitions at the same time—the qualifying higher plant and the precision bred organism. I want to make this point because it is important, given some of the contributions that have already been made. There is a further problem as the European Union has a different term for what looks like an attempt to define much the same thing—an NGT, or a product of new genetic techniques. I do not want to rile Government Members by suggesting that that might be a better name for what we are doing, but it probably captures more accurately what we have discussed so far, because these are indeed new genetic techniques, and will probably go on being new genetic techniques.
Does that matter? I think it might, and that is the problem. It goes back to the points made earlier by the hon. Member for Edinburgh North and Leith. The movement of goods and materials across borders is vexed at the best of times, and pretty fraught at the moment. The trade implications are explored in section 6 of the impact assessment, which makes interesting reading with some quite bold assertions. I will refer to them because, although the view of the Government is that this probably will not be a problem, they do to their credit go into what could occur as a consequence of it becoming a problem. It is pretty alarming. Should there be a dispute, the impact assessment states:
“This would have a relatively significant impact on UK producers…UK crop-related food exporters are heavily dependent on EU consumers’ demand. Approximately 55% of all crop-related food exports from the UK are to the EU…And so, it would be difficult to replace EU demand. Therefore, there is a possibility for a portion of the £8.56 billion worth of crop related exports to the EU to decrease, potentially outweighing the scale of direct benefits to business. Nonetheless”—
This is very reassuring—
“this represents only 2.5% of our annual total value of exported goods and 5.4% of our annual value of exported goods to the EU. And so, even if UK crop-related food exports are maximally impacted, the overall impact on the UK balance of trade is minimal.”
Well, I do not think it will come as a great reassurance to those involved in the sector if that is part of the potential risk.
There are big risks here. Not only do we have that issue, but there is also the wider issue of the Cartagena protocol, which governs the movement of these organisms across borders. I suspect that by introducing the precision bred organism, we are introducing a new category, which again leaves us open to challenge. In all these cases, the argument will always be, “Is it in anybody else’s interest to challenge?” What we know from all these trade negotiations is that if there is any possibility of someone picking a fight, they can always use something like this to pursue it.
In conclusion, we are stepping into some tricky territory. We generally hope that other countries will come with us in similar ways and that any differences can be resolved without recourse to challenge, but we should be aware of those risks and proceed with care. Investors will ask themselves a simple question: is there a risk here, and if so, does the potential benefit outweigh the potential disadvantage? It has been suggested—indeed we heard it in the evidence from the Agricultural Industries Confederation—that there is a concern that people will look at the legislation and think, “This is not very certain or clear. We will wait and see what others do first.” Far from speeding things up, we could end up delaying them. The Government need to show that these questions have been addressed and answered. This is a small clause, but it has occupied quite a lot of time and is hugely significant to how we go forward.
Jo Churchill
The approach we have taken to regulating genetically modified organisms has not kept pace with scientific progress. The hon. Gentleman referenced the UN’s Cartagena protocol on biosafety, in which “modern biotechnology” is a term used. Its definition of modern biotechnology aligns with techniques such as those listed in sub-paragraphs 5(1)(a) and 5(1)(b) of the Genetically Modified Organisms (Deliberate Release) Regulations 2002. We are using the same list of techniques in this clause—see subsection (3)—to ensure that the new regime fits neatly alongside the one that regulates GMOs without leaving gaps or overlaps, which I think is the right course of action to ensure that nothing slips through the cracks, and without bringing any organisms that are not currently regulated as GMOs into the new regime regulating PBOs.
Some 30 years ago, modern biotech was used to transfer DNA between very different organisms. It can now be used to introduce changes that could have occurred naturally and through the use of traditional processes. As we have heard, that makes it much more targeted. The legislation controlling organisms produced by modern biotechnology needs to reflect these developments and our increased knowledge. Most notably, the science is telling us that we should not regulate precision bred organisms differently from their traditionally bred counterparts.
Clause 1 describes precision bred organisms, which we are carving out from legislation on the release and marketing of genetically modified organisms. The definitions have been drafted using the latest scientific advice, and they are designed to ensure that this regulatory system can work. We are taking a critical step towards proportionate, science-led regulation of genetic technologies. As highlighted by Sam Brooke in the evidence sessions, the Bill will encourage greater research, innovation and investment in precision bred technologies. In doing so, it will lead to environmental, health and economic benefits for the UK.
It is vital that we add precision breeding to our toolbox to help us address some of the challenges we know we are facing, not only as a country but globally. The hon. Member for Cambridge referred to the SI. This will be revoked when we introduce secondary legislation after the Bill passes. I commend the clause to the Committee.
Question put and agreed to.
Clause 1 accordingly ordered to stand part of the Bill.
Clause 2
Meaning of “plant” and “animal”.
Question proposed, That the clause stand part of the Bill.
Jo Churchill
Clause 2 defines “plant” and “animal” for the purposes of the Bill. The definitions in subsections (1) and (2) cover multicellular plants and animals; they do not cover micro-organisms. The clause expressly excludes humans from the scope of the Bill. Under current legislation, humans and human embryos cannot be classed as genetically modified organisms, and nor will they be classed as precision bred organisms under the Bill. Subsections (3) to (5) establish the developmental stage at which a plant or animal falls into the scope of the Bill, by defining what is meant by an organism.
Daniel Zeichner
I am sure that everyone will be relieved to know that this is going to be a quicker debate than that on the previous clause. The clause appears to be quite straightforward, defining the terms “plant” and “animal”. I have one question. Subsections (3) and (4) mention gametes. Subsection (3)(a) states that references to plants and animals
“include an embryo and all subsequent developmental stages of an organism”.
For plants, references include
“a seed or a vegetative propagule”
but
“do not include a gamete.”
Could the Minister explain why gametes are not included in the definitions and what purpose their mention in the clause serves?
Jo Churchill
Please bear with me as I go through my copious notes. Will the hon. Gentleman repeat what part of the clause he was referring to?
Daniel Zeichner
Subsections (3) and (4). What is the purpose of those subsections, because it is not entirely clear to me?
Jo Churchill
The gamete contains only half of the genetic code required to reproduce a whole organism. A whole functioning plant or animal cannot be generated from a gamete and is therefore not considered an organism for the purposes of the Bill. I hope that answers the hon. Gentleman’s question.
Daniel Zeichner
It is certainly an answer to the question—I am not sure it is an answer I fully appreciate and understand, but I will go away and look at it further. I am grateful to her for that answer.
Jo Churchill
I am very grateful for the question. As he and I both know, I have learned an awful lot about all these particular things going over all the details. If there is anything further, I would be happy to answer.
Question put and agreed to.
Clause 2 accordingly ordered to stand part of the Bill.
Clause 3
Restrictions on release of precision bred organism in England
Daniel Zeichner
I beg to move amendment 32, in clause 3, page 3, line 35, at end insert—
“(c) the organism has been developed for or in connection with one or more of the following purposes—
(i) producing food in a way that protects or enhances a healthy, resilient and biodiverse natural environment;
(ii) growing and managing plants or animals in a way that mitigates or adapts to climate change;
(iii) producing food in a way that prevents, reduces or protects from environmental hazards;
(iv) protecting or improving the health or welfare of animals;
(v) conserving native animals or genetic resources relating to any such animal;
(vi) protecting or improving the health of plants;
(vii) reducing the use of pesticides and artificial fertiliser;
(viii) conserving plants grown or used in carrying on an agricultural, horticultural or forestry activity, their wild relatives or genetic resources relating to any such plant;
(ix) protecting or improving the quality of soil;
(x) supporting or improving human health and well-being;
(xi) supporting or improving the sustainable use of resources.”.
This amendment would require that a precision bred organism has been developed to provide a public benefit, if it is to be released into the environment.
Kerry McCarthy
That is a fair point. Hopefully we will come to that when we get to clause 17.
To conclude, Joanna Lewis at the Soil Association talked about this “unhelpful trajectory”, and how that is in conflict with the Government’s goals on the sustainable farming transition. She says:
“We therefore need to ensure that we are not accelerating that trend through carte blanche deregulation.”—[Official Report, Genetic Technology (Precision Breeding) Bill Public Bill Committee, 28 June 2022; c. 56, Q92.]
I agree. She goes on to say that there is an opportunity to put good governance at the heart of the Bill, and to get that public interest test in there, which I support.
Jo Churchill
Amendment 32, as I understand it, would embed public interest into the Bill. We are very much aligned with the intentions behind the amendment, and are already undertaking a range of work across Government that delivers public good. Some of those have been mentioned. We want precision breeding technologies to deliver real benefits. They are a vital part of toolkit to deliver benefits for our food system and the environment. The hon. Member for Bristol East said—rather, implied—that our farmers were not doing the right thing.
Jo Churchill
Well, if they are doing the right thing and our researchers are, too, there is no need for that reassurance in the Bill. Throughout the Bill there is the PBO assessment via ACRE on both plants and animals; the animal welfare declaration and the animal advisory body; the PVS varieties listing for plants and seeds; the FSA and the food and feed marketing authorisation to check before food comes to market. There are checks and balances throughout the Bill. We are keen to see those things in the Bill that can deliver good—disease resistance, pest resistance and drought resistance.
Fay Jones
Does the Minister agree that this legislation is simply a tool to help the industry to carry on the good work that it has already been doing? We have talked about antibiotic use in agriculture. Since 2014, through the responsible use of medicines in agriculture, antibiotic usage has reduced by 50%. We are the fifth lowest user of antibiotics across the European Union. Does she agree that this legislation simply helps the industry carry on that good work?
Jo Churchill
I agree very strongly that we should allow our farmers and fishermen to optimise research, with the appropriate checks and balances, to ensure they can bring to market produce that is trusted by the consumer and safe. That is exactly what our system has been set up to deliver. It is really important that they can use cutting-edge science to help them deliver those benefits. I believe we are on the same trajectory; we are just having a worthwhile discussion about whether things should be on the face of the Bill or should be embedded in our systems.
Daniel Zeichner
Will the Minister comment on the point I made about the development of herbicide-resistant varieties? We know there has been an issue with glyphosate and so on. That is not necessarily something that we would all welcome. Is there anything in the Bill that would allow the Government to express a view on whether that is beneficial?
Jo Churchill
If the hon. Gentleman will allow me to carry on speaking, I may well get to his point. The research is there to drive forward the ability to grow sustainably. He referred to the altruistic way in which Bill Angus approaches his work. We also heard from Professor Cathie Martin. She had that enthusiasm, but I am sure that many Members heard her contention that if she could get more of the population eating more fruit and vegetables, she would feel that she had really driven things forward and used these technologies to deliver a public good.
Although I understand the intention behind the proposal, I do not think it is necessary because it applies to release into the environment. That is principally covered in field trials, which are crucial to building our understanding of how genetic changes impact organisms under field conditions. They are an integral part of pure research, as well as breeding programmes.
Once again, I come back to the fact that we are at the start of this journey. We already know that the UK is delivering positive research. Professor Martin from the John Innes Centre spoke about the vitamin D tomatoes that her group is developing. We also heard about her commitment to strive towards improving the food we eat for the benefit of our health. It is important that such research proposals, which are often supplemented by money from the public purse, both in Scotland and in England and Wales, go through these assessments. We did not hear from just one person; we heard from many conducting the research. We should be proud of the research and the regulatory framework, which I believe is in place through ACRE, the varieties listing and the animal welfare declaration, for products brought to market—we will discuss that when we come to the provisions in part 3.
We do not think it is necessary to place restrictions on research using these technologies. We have no evidence to suggest that developers are doing anything that would fall outside the purpose of the Bill. The checks and balances, and the fact that ultimately it can be withdrawn if there is a concern over the technology—that is later in the Bill—give us what we need. We are striving to deliver public good.
As can be seen in the Agriculture Act 2020 and the Environment Act 2021, and in the sustainable farming incentive and environmental land management schemes, we are committed to developing a more sustainable and resilient food system, to ensuring and even enhancing animal health and welfare, and to protecting the environment. Recently, we announced the food strategy, which sets out a plan to make sure that we have a food system fit for the future, with sustainability from farm to fork and from catch to plate. We want to seize the opportunities and ensure everyone has access to nutritious and healthy food.
11 am
We are also committed to funding innovation. We have put over £130 million into joint funding with UK Research and Innovation for food systems research and innovation, £100 million into the UK seafood fund, and £270 million into farming innovation. We have invested £11 million to support new research to drive improvements in understanding the relationship between food and health. In total, that is over half a billion pounds, which should show the level of the Government’s commitment. Through the net zero strategy and the national adaptation programme, the Government have as a top priority mitigating and adapting to the impacts of climate change. Our commitment to the environment is demonstrated through the 25-year environment plan. The Bill can help with all of that. We see precision breeding as an enabling tool to help us to achieve objectives across these critical areas. Public good is very much embedded in what we are already doing and aligned with the interests of our researchers in the UK, and the checks and balances are there to ensure it.
I will end by restating the principle of the Bill, which is to regulate these technologies more proportionately to their risk. Placing additional regulatory requirements goes against that principle, and against the science and evidence. I ask the hon. Member to withdraw the amendment.
Daniel Zeichner
We have had an interesting and wide-ranging exchange, which touched on a series of the broader principles behind the Bill.
To respond to the interventions from Government Back Benchers, my concern is that when we look at the power relationships in the food system, we see that farmers and producers are not always in the strongest position. Quite often, they are under pressure, and they will be under particular pressure given the price issues that they face at the moment. Frankly, the people who are looking to invest in these new technologies, particularly the big players, will look for proper returns. That is perfectly proper; it is exactly what we would expect them to do. From the point of view of the individual producers, whether of crops or animals, people further up the chain may, in essence, be saying, “We’ve now got this tool and we want you to use it.” It is pretty clear that a lot of farmers pretty much have to do what they are instructed to do by people further up the chain. Consequently, the question whether something is in the “public good” or not becomes a very difficult one for people who may well want to do the right thing.
It also goes back to my question, which I am afraid the Minister did not address, about herbicide-resistant traits. That has been an issue previously, and we know that not all the developers of these technologies are looking to achieve the wider public good. Sometimes, all they are seeking to achieve is market domination and a significant return for themselves. That is not surprising, because that is what some of them are in business to do. What are we as legislators to do to protect wider society and our producers from that kind of pressure? I am not saying that will necessarily happen immediately, but the danger will be that if there is not any protection against that kind of thing, it can happen.
That is why I genuinely do not understand why the Government would not want this amendment to the clause, because everything the Minister said, which I think all of us would agree with in terms of the potential benefits and the good things that people are trying to do, would all be captured within a public benefit test like the one we propose, and only the things that we would not want to see would be discouraged by it. There is nothing to fear. Perhaps we should have spent more time on this during the evidence sessions, but my understanding is that other jurisdictions have introduced some kind of public benefit test for exactly the reasons I am outlining.
The issue goes right back—and I think we will keep going back to it—to where we started: what kind of regulatory framework we are setting up. At this point, I have to say that I think there is an ideological divide between the Government and Labour. Essentially, this is a highly deregulatory Bill—essentially it is saying, “Leave it to the market”. The market will do what the market will do: pursue the best possible return. Whether that always delivers the right societal return in environmental benefits and so on is a moot point. I think there is a genuine difference of opinion between us. The Opposition are clear that we would include such a public benefit test, because we are not convinced that the proposed framework will always work for the public good.
I will not waste the Committee’s time by having endless, pointless votes. I will withdraw amendment 32, but the Opposition would like a vote on amendment 10, because we think that it is significant. I beg to ask leave to withdraw the amendment.
Amendment, by leave, withdrawn.
Clause 3 ordered to stand part of the Bill.
Clause 4
Release of precision bred organism: notification requirements
Amendment proposed: 10, in Clause 4, page 4, line 24, leave out “negative” and insert “affirmative”.—[Daniel Zeichner.]
Question put, That the amendment be made.
Jo Churchill
We have moved on at some speed. The clause builds on clause 3 and sets out the requirements for notifying the Secretary of State before a precision bred organism is released into the environment for purposes other than marketing, in particular for field trials.
Under the clause, the Secretary of State has powers to make regulations, establishing the form and content of notices that must be submitted before a trial can take place and the information that must accompany them. That will enable us to tailor what information we ask for, which may be placed on a public register, to ensure that the requirements remain relevant and appropriate.
The clause also allows for regulations to be made establishing who can be specified in a release notice and for a minimum time period to be set between the submission of that notice and when a trial can take place. Regulations made under the clause are subject to the negative procedure. The clause will enable us to develop and expand the proportionate pre-trial notification regime that we introduced earlier this year in respect of plants to all precision bred plants and animals.
Daniel Zeichner
Clause 5 concerns restrictions on marketing precision bred organisms in England. I do not have a lot to say about it, other than to explore with the Minister how it will be determined that a precision bred organism is indeed that; this goes back to the earlier, earlier debate.
My understanding is that the determination will be based on the definition, agreed by the Committee, as something edited using modern biotechnology in a way that could have occurred naturally or through traditional breeding processes. Can the Minister say more about how it will be determined that the organism could have been produced in that kind of way? What kind of evidence will be sought and how will the whole process work? It is not entirely clear to me from the Bill as written.
Jo Churchill
I refer the hon. Gentleman to the ACRE process and the guidance from the penultimate evidence giver, Nigel Moore. The ACRE guidance lays out how it will be determined, which is part 1 of the PBO assessment. I refer the hon. Gentleman to the guidance notes because they lay out very specifically and clearly how that will be determined.
Daniel Zeichner
I suppose my concern is that this seems to be a very closed world in which a group of eminent and expert people are involved in making judgments. There is no external input. Given that all those people basically work in the same institutes, is it not a rather closed system?
Jo Churchill
I believe nomination to ACRE works to the Nolan principles. Yes, those people are eminent, but they are also held in high esteem and regard and have to work to those Nolan principles when acting in the capacity of their position on that committee. It is difficult to unpick who the hon. Gentleman would see as the most qualified, if it is not those who are elected by their peers and go through an appropriate system. They must have the expertise because it is important that those who are determining know what they are doing; otherwise, with the greatest of respect to the hon. Gentleman, he and I would be a lot less enabled.
Daniel Zeichner
I return to a point I made when we discussed the statutory instrument. I am in no way trying to question the integrity of those who sit on those committees. However, when we look at their declaration of interests, almost all—perhaps inevitably—are linked to some of the major industries in the field.
I ask the question again. Does the Minister genuinely believe that the system and set-up will fill the public with confidence or will they look at it and worry?
Jo Churchill
I think most people will see it as proportionate and want to have those who are expert in the field making judgments. It is they who will say whether the technology is a PBO and can move forward. The hon. Gentleman’s argument slightly falls down because the issue applies to just about every overarching body, in that they have, by definition, some knowledge of the issue on which they are deciding.
Question put and agreed to.
Clause 5 accordingly ordered to stand part of the Bill.
Ordered, That further consideration be now adjourned.—(Gareth Johnson.)
Genetic Technology (Precision Breeding) Bill (Third sitting)
Jo Churchill ExcerptsThursday 30th June 2022
(2 years, 5 months ago)
Public Bill CommitteesRead Full debate Genetic Technology (Precision Breeding) Act 2023 View all Genetic Technology (Precision Breeding) Act 2023 Debates Read Hansard Text Read Debate Ministerial Extracts Amendment Paper: Public Bill Committee Amendments as at 30 June 2022 - (30 Jun 2022)
The Chair
We will now hear oral evidence from Professor Gideon Henderson, chief scientific adviser at DEFRA, who is with us today in person. Before calling the first Members to ask a question and before allowing the professor to introduce himself, I remind all Members that questions should be limited to matters within the scope of the Bill, and that we must stick to the timings of the programme motion that the Committee has agreed. That means that for this first session we have until 11.45 am. Professor, would you like to introduce yourself briefly? Then we will start with questions from the Minister.
Professor Henderson: Hello. My name is Professor Gideon Henderson and I am chief scientific adviser at DEFRA.
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
Q
Professor Henderson: I am content that this Bill is scientifically sound. I have given it a great deal of attention and have called on a great many expert witnesses through informal and formal processes. I have interacted with a large number of stakeholder groups over the past 18 months, and I am content that there has been due scientific scrutiny and that this Bill is based on sound science and agreed science.
It is important to move forward with this Bill for several reasons. There are very significant benefits to the environment, human health and resilience to climate change that can accrue from precision bred organisms. The technologies that we can harness to derive those benefits are now sufficiently mature that we are ready to capitalise on them. The UK is well positioned to do that. Many other countries have already made the use of such technologies easier, and it is time for the UK to catch up and it is safe to do so.
Jo Churchill
Q
Professor Henderson: There are two sides to my answer, one of which is the scientific side. The scientific body of knowledge is, of course, shared across the world and certainly across the four nations, and there is strong expertise in gene editing and the technologies we are talking about today in the devolved nations, as well as in England—certainly, those strengths are quite considerable in Scotland and Wales. The UK as a whole is very strong in this area, scientifically.
At a governmental level, there have also been significant discussions between Government scientists. I talk to my counterparts in Scotland, Wales and Northern Ireland, and I have been sharing information with other officials and sometimes with Ministers in the devolved nations as well. I think there is agreement about the science across the four nations, but not always about the policy direction.
Daniel Zeichner (Cambridge) (Lab)
Q
I will not be repeating the questions we went through last time, but go on to some other things. I was particularly struck by the written evidence from the Nuffield Council on Bioethics, members of which we will be hearing from later, and I want to put to you a couple of the questions that were raised in their evidence. They talked about something that I do not think we were aware of, which is that the Department is looking at its advisory frameworks in general. In reference to the Bill, obviously the Advisory Committee on Releases to the Environment looks like it will play a significant part, so could you say a little bit about what discussions have been had as to whether that is really the appropriate body, or whether some new body should be formed to oversee these complicated trade-offs and issues?
Professor Henderson: There are a number of things that that might refer to. There is a periodic review of how we get advice—scientific and otherwise—into DEFRA, and such a review is ongoing at the moment. I think it is entirely safe to say that that will not impinge on ACRE’s activity. It serves a critical function already, and has an expanded role through this Bill to identify when things are precision bred organisms and when they are not. To me, that body seems to be the right place to attend to that type of decision about whether something is a PBO or not. There are also questions about animal welfare, and it may be that other bodies are required to adjudicate in that area, but that is for further down the line.
The Chair
We will now hear evidence from Professor John Hammond, group leader of genetics, genomics and immunology at the Pirbright Institute. He will be appearing via Zoom. We will also hear from: Professor Bruce Whitelaw, director at the Roslin Institute, who is with us in person; Dr Craig Lewis, genetic services manager Europe and chair for the European Forum of Farm Animal Breeders at Genus, also with us in person; and Dr Elena Rice, chief scientific officer at Genus, who is appearing via Zoom. The session will run until 12.25 pm. Starting with Professor John Hammond, will you all briefly introduce yourselves, before we go to questions?
Professor Hammond: I am Professor John Hammond and I work at the Pirbright Institute. I look after the science responsible for improving post-livestock genetics to increase disease resistance and resilience.
Professor Whitelaw: Hello, I am Professor Bruce Whitelaw. I hold the chair of animal biotechnology at the University of Edinburgh. I am also the director of the Roslin Institute and have led projects there that have generated genome edited livestock.
Dr Lewis: I am Craig Lewis. In my current role I oversee the implementation, design and execution of practical animal breeding programmes for a subunit of Genus called PIC. Prior to that, I hold advanced degrees in animal genetics, from Roslin, and animal welfare.
Dr Rice: Good morning. I am Elena Rice and I am the chief scientific officer for Genus. I am overseeing the research programme across our business units, PIC and ABS. We are a world leading animal genetics company.
Jo Churchill
Q
Professor Hammond: Where we have got to with the precision breeding methodologies in the Bill now supports decades of primary research in the UK and other countries. We understand the complex genetics underlying health traits and, in particular, disease resistance, which is a complex biological process. Because of those advances, and the work that we and others are doing, we are identifying genetic variants that may exist naturally, which, in combination or isolation, can dramatically increase disease resistance and resilience in farm animals.
The ability to undertake precision breeding, which would be the equivalent to the natural variation that we find in those populations, is an almost transformative technology to improve animal welfare and production—for example, there would be a lack of wasted carbon caused by disease. I think it has a really important potential for planetary health in terms of climate change.
Jo Churchill
Q
Professor Whitelaw: Roslin has been involved in a number of species: pigs, cattle, small ruminants and poultry, primarily chickens. We are also now looking at research to do with aquatic species. The main driver of that research has been to reduce stress impact on the animals, and we have focused on disease, partly because it is one of the main stresses imposed on animals around the world, but also because we have a lot of knowledge. As my colleague John just indicated, we have a lot of genetic knowledge and a lot of knowledge around the actual pathogens themselves.
There are two projects that have the highest profile. One is to do with pigs and relates to a disease called porcine reproductive and respiratory syndrome, and we have done that in collaboration with Genus PIC. The other area we have been looking at extensively is around influenza—primarily in chickens and poultry, but also in pigs—and there are other diseases behind that. From a research perspective, disease is a very challenging topic, but we have a lot of knowledge. There are other stresses that we are looking at, such as heat tolerance. We are looking at the impact of reproductive issues on animals, and these can all be addressed by using genetic technologies, including genome editing.
Jo Churchill
Q
Professor Whitelaw: We are very fortunate that we punch above the size of our island and have been leading in the area of livestock for some considerable time. We all know the reason why Roslin has a high profile: it is because of a certain sheep called Dolly, which was 26 years ago. That whole project was around genetic engineering, and the same exists in the plant community. We have some really strong players in the academic arena. We do not have the numbers that exist globally, but we do sit very well within that. I will quite happily say we are leading, and I will quite happily say that Roslin is a leading player in that too.
Jo Churchill
Q
Dr Lewis: To put it into some context, I grew up on a pig farm in Herefordshire, so I have seen PRRS, or what was called blue ear disease here in the UK, at first hand with my father. The focus of my PhD work at Roslin was actually looking for natural variants in terms of PRRS resistance. Are there pigs out there—even today—that we could selectively breed so that we would not have to deal with this problem or could at least make the animals more robust? After three years at Roslin, the bottom line was that although we do a great job at creating genetic improvement to make more robust pigs generally—we can increase feed conversion, growth rate and so on—specific disease resistance is obviously a very complicated trait. This is an opportunity where we can almost create a natural variant, and therefore the mutation in the particular genome that confers the resistance; it would be wonderful if that just happened in the next generation completely naturally, but this is not a fairy tale—it is practical animal breeding. The ability to be able to create that variant so that we can actually implement this in a practical breeding programme, as John said at the beginning, is game-changing technology.
In terms of how that could impact globally, PRRS is endemic in multiple markets around the world. I have worked across the United States, which is very impacted by this particular disease. Right now, Spain is going through a very nasty strain of the PRRS virus. Here in the UK, whether it is indoor intensive units or the outdoor pig units in Norfolk, East Anglia, which we see when we drive around, we have PRRS outbreaks. That is a difficult scenario, for the pigs, obviously, in terms of morbidity and mortality, but there is also a human element. People like my father are deeply impacted when their animals are sick. Fundamentally, that is why I got into science. The scope of delivering truly disease-resistant animals impacts so much, as we look at this technology.
To get into the science, I will hand over to my colleague, Elena.
Dr Rice: The question was where are we today with the development of PRRS-resistant pigs. Today, we have quite a large population of animals that are not the first generation. We did the edits and already bred animals that carry the resistance to the virus. Those animals have been tested in disease challenges and we showed that they are completely 100% resistant to the virus. Because of this small edit in one gene, those animals do not see the virus and cannot get sick, which means that they do not require extensive application of antibiotics on the farm. In our process, we are building a commercial herd now. We are going through the accrual process with the US Food and Drug Administration. The process is very successful. We are moving forward and are actually accelerating our studies. We hope to see approvals in late 2023 or the beginning of 2024. So this is real and it is here.
We are also working with regulatory agencies in other countries, such as Japan, Canada and South Korea, and we are expanding our interaction with many other countries. What we see today is that there is a very clear path in all those countries to get approval for the animals and bring them to the market.
The Chair
A number of Members have signalled that they want to speak. I remind Members that this session goes to 12.25 pm. I will start with Daniel Zeichner.
Jo Churchill
Professor Hammond might be interesting on this, because he deals with avian flu, and obviously that might broaden it to the wild community.
The Chair
If you want to do that, you have less than a moment. It is for all Members to direct the questions to who they would like to hear answer them.
The Chair
We will now hear oral evidence from Dr Peter Mills, assistant director at the Nuffield Council on Bioethics, who is with us in person; Dr Madeleine Campbell, British Veterinary Association member, RCVS recognised specialist in veterinary reproduction and European diplomate in animal welfare science, ethics and law, who is appearing via Zoom; and Peter Stevenson OBE, chief policy adviser at Compassion in World Farming. This session lasts until five minutes past 1. Again, if everybody could be mindful of that and direct their question to the witness they would like to answer it. Could each of the witnesses introduce themselves for the record, starting with Dr Peter Mills?
Dr Mills: Good afternoon. I am Dr Pete Mills. I am assistant director at Nuffield Council on Bioethics.
Dr Campbell: Good afternoon. I am Dr Madeleine Campbell. I am the current chair of the British Veterinary Association’s ethics and welfare advisory panel. If I may briefly correct something you just said, I am actually an RCVS recognised specialist in animal welfare science, ethics and law and a European diplomate in animal reproduction.
Peter Stevenson: I am Peter Stevenson. I am chief policy adviser at Compassion in World Farming. I am a solicitor by background, although I do not do all that much legal work nowadays.
Jo Churchill
Q
Dr Campbell: To clarify, I did indeed argue that at a recent Animal Welfare Foundation event in the course of a debate. I was slightly making an argument, but yes, we do feel that genetic editing of animals could play an important role in enhancing animal welfare and in the broader context of enabling agriculture to develop in a sustainable way, which would minimise the impacts of animal agriculture on the climate and the environment. Yes, it has great potential to do good, but it also has great potential to do harm from an animal welfare point of view. As I say, it needs to be thought about very carefully.
Jo Churchill
Q
Dr Mills: The Bill is a very welcome initiative. The Nuffield Council does not believe that the retained EU regulatory regime is fit for purpose. One of the shortcomings of that regime was the way in which it was relatively indifferent between plants and animals. We believe that the potential power of genome editing as a technology merits some control, so we are pleased that the Government have brought forward this Bill to do that.
The Bill addresses a number of potential mischiefs that could occur as a result of the use of those new technologies. It is perhaps a little bit unambitious in the sense that it leaves a vacuum at the heart of the governance system that applies to breeding technologies. You heard evidence in the previous session about the Animals (Scientific Procedures) Act 1986, which is primarily focused on experiments on animals. The Animal Welfare Act 2006 was also mentioned, which is to do with the treatment of animals in different settings. There is nothing at present that controls the production of animals of particular kinds.
The precision breeding Bill—despite the title—does not, in a sense, control precision breeding or genetic technologies, except indirectly by causing breeders to anticipate the conditions under which they will be able to market the products of their breeding. What is missing is some more positive statement or principle about the purposes for which precision breeding—and breeding more generally—might be used. As we argued in the Nuffield Council report, breeding of all kinds should be directed towards securing a just, healthy and sustainable food and farming system. Having something like that in the Bill as a framework, within which standards can be elaborated through regulations and by the relevant authorities, would be extremely helpful.
Jo Churchill
Q
Peter Stevenson: I am afraid that I have serious misgivings about gene editing. I think it is going to do a great deal of harm, both during the creation of gene edited animals and then when it is used on farms. Having said that, I recognise that there will be certain cases where it can be beneficial. For example, Compassion in World Farming is working quite closely with a company that is trying to gene edit hens to not produce male chicks. That would prevent millions of male chicks being killed at a day old every year. We are not totally against it.
For me, at the root of the problem is that the Bill argues that gene editing is just a more precise form of traditional breeding, such as selective breeding. If you look at the last 50 years, selective breeding has caused immense health and welfare problems for farmed animals. Meat chickens have been bred to grow so quickly that millions suffer from painful leg disorders each year, while others succumb to heart disease. We have bred dairy cows to produce such high milk yields that many are suffering from lameness, mastitis and reproductive disorders, and the cows live with these welfare problems for a large part of their lives. We have bred hens to produce 300 eggs a year. As a result, many suffer from osteoporosis, making them highly susceptible to bone fractures.
The idea that we will push all this further through gene editing is really worrying, but if we are going ahead with this, which is the clear intention, I think—I am now speaking as a solicitor—that the animal welfare protections in the Bill are drawn in very broad language. They are imprecise and unclear, and they need to be given more focus and strength, so I would love the Government to revisit those provisions.
Jo Churchill
Q
Peter Stevenson: In 30 years of working in this field, I have never tried to assert anything that is not supported by the science. I have tried to say that gene editing could be helpful in certain and very limited circumstances, but that it will be harmful overall. The science about the detrimental impact of selective breeding on just about every main farm species is utterly clear. There is a huge amount of science on the subject, some of which comes from the Farm Animal Welfare Council, which is now called the Animal Welfare Committee. I totally reject any suggestion that what I have said about the damage done by selective breeding is not based on the science. As I say, the idea that we will push this further and drive animals to even higher yields, faster growth and larger litters through gene editing is really disturbing.
Daniel Zeichner
Q
Dr Campbell: That is a key question. When we talk about whether gene editing will be beneficial or detrimental from an animal welfare point of view, as we have just been discussing, we need the evidence to look at that. I do not feel that the Bill as drafted will provide a mechanism for doing that.
At the moment, the Bill has a mechanism specifically for applications for marketing authorisations to be referred to the animal welfare advisory body. It is somewhat open in Bill as to exactly what that body is, as I understand it; it could be an existing body, or a new one. What will be crucial is that we have a proper mechanism in place to have oversight not only of the marketing and the release of any genetically edited animal organisms, but of the actual processes that are going on with the so-called precision breeding, so the animal welfare advisory body needs to have oversight of those processes as well, and that needs to be an obligatory oversight. It needs to have an obligatory reporting role too.
This needs to be an independent body, with suitable expertise to understand and interrogate both the basic science and the animal welfare science, and to understand and explain the ethics around that. It must be independent of Government and of scientists, and it must be independent of any lobbying—around trade, for example. Then it needs to be able to look both proactively and retrospectively at data about the health and welfare of animals that are produced using so-called precision breeding techniques. It would be an independent oversight body—in my mind’s eye, very analogous to the Human Fertilisation and Embryology Authority—that can take an independent look at the data and then make recommendations for policy changes in light of that data, as the science develops.
Genetic Technology (Precision Breeding) Bill (Second sitting)
Jo Churchill ExcerptsTuesday 28th June 2022
(2 years, 5 months ago)
Public Bill CommitteesRead Full debate Genetic Technology (Precision Breeding) Act 2023 View all Genetic Technology (Precision Breeding) Act 2023 Debates Read Hansard Text Read Debate Ministerial Extracts Amendment Paper: Public Bill Committee Amendments as at 28 June 2022 - (28 Jun 2022)
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
Q
Professor Lovell-Badge: I am, yes.
Jo Churchill
I would like to take a little from the narrative that you have given us, and from something that you stated in your returns to the consultation. Thank you for saying that the Bill has been consulted on widely; we are trying to get it right, so any advice would be gratefully received. You stated:
“If appropriately managed, precision breeding offers a route to achieving many potential and much-need benefits to society.”
That rather articulates your argument that it is outcomes-based. With that in mind, you stated that you support the advice of the Advisory Committee on Releases to the Environment that precision breeding poses no greater risk than traditional breeding methods. Can you explain why, and can you refer to whether you think the current regulatory framework has held up? I think that was what you were saying in the narrative about research and development. Where would you go with that regulatory framework in order to optimise the R&D so that we can evolve into being outcomes-based, both in environmental and human health terms?
Professor Lovell-Badge: Right. There is a lot there.
Jo Churchill
There is a lot there, but there was a lot in your opening remarks to try to encapsulate.
Professor Lovell-Badge: The first question was about risk, I believe. Generally, on the risk of a random mutation versus a genome-edited one, you are actually better off with a genome-edited one because you know what you are doing. Of course, there can be some examples where you might not know exactly what is happening. There is very little mention of human health in here and so there is concern about zoonosis, where an animal virus can jump to humans, for example. You could, in theory, make what you think is a fairly simple change to give a trait that you want, but inadvertently you allow an animal virus to jump to humans. That needs to be looked at, in terms of risk. Exactly the same thing can happen with traditional breeding, but I imagine it is not generally looked at. That is a risk.
Alessandro Coatti: The case that Robin used before is quite important, where you think about adding multiple changes to genes in the same organism. The Bill covers plants and animals, but it does not cover micro-organisms, which are an interesting aspect that we can discuss later. You also really have to think about the fact that the dynamics of the genomic changes in different organisms are different, just like the way they reproduce is different. The type of gene flow that you would see in plants is different from the one you would see in animals.
The case that Robin was discussing of adding multiple changes in neighbouring genes in an animal is harder, through traditional breeding, than it has been in plants. For example, you can mutagenise into this very big screening. You might get to that point faster in plants than in animals. Perhaps the fast pace where this technology now allows development is not, as you say, either a morally or a practically neutral question. It is interesting that the Government have decided to frame it as something that could have arisen through traditional breeding or spontaneously. There is a reason why that is. However, at some point, it becomes a bit stretched, because in traditional breeding it would take many generations, and it would be quite hard to do it in certain animals.
However, this is again talking about the techniques. When it comes to adding those two traits in neighbouring genes, you might end up actually making the life of the animal way better. That is why you look at the outcomes. By using genome editing, people have corrected genetic defects that have arisen traditionally in breeding, for example of cattle. There is this Japanese breed of cattle that has a genetic syndrome. With genome editing, they corrected it because it was due to a single gene. In fact, even if it were very unlikely that you might have done it with traditional breeding, it is a very valuable use and we should do that because it enhances the welfare and the health of the animal.
Jo Churchill
Q
Professor Lovell-Badge: The question would be: if someone made a plant or an animal where you have targeted two adjacent genes, would that be permitted or not under these rules? It is hard to think that it might be, because you could not simply do it by traditional methods. You might have to wait thousands of years and it would cost you a lot of money. That is the question.
Daniel Zeichner (Cambridge) (Lab)
Q
I want to explore something slightly different: the role of advisory bodies. You began to touch on that in your last answer. The Bill at the moment is very thin on what the advisory bodies are there to do. In some of your written evidence, both your organisations suggested that the different bodies should have some kind of remit to look at the wider public good. Could you say a little bit about that? I have been taken by the example of the Human Fertilisation and Embryology Authority, or some aspects of the work that it does.
Professor Lovell-Badge: I have been very much involved in the HFEA public engagement exercises. When you are considering a broad area, or potential uses and outcomes, it is really important to have proper public engagement, including democracy, dialogue, or however you want to refer to it, where you really get to understand what the public will think about a topic.
When it comes to assessing technical aspects, it will be challenging. It is fine to have a lay member on a panel, but I do not know whether consulting the public about really detailed, technical issues might be challenging. It depends on what the advisory committee’s role is and whether it is to look more broadly at potential uses and outcomes or to focus on the specific techniques that are being used.
The Chair
We will now hear oral evidence from William Angus, owner of Angus Wheat Consultants Ltd, who will join us via Zoom, Professor Johnathan Napier, research group leader, and Professor Nigel Halford, who is a crop scientist. Both are from Rothamsted Research and are with us in person. Could you introduce yourselves for the record? I will go first to William Angus.
William Angus: My name is Bill Angus—christened William, but anyway. I am a wheat breeder, and my job is to breed new varieties of wheat. I have been doing it for quite a long time. I started in the public sector at the Plant Breeding Institute, and then moved to the private sector with Nickerson. I started my own wheat breeding and oat activities in 2016, which has resulted in us being the largest privately owned wheat and oat breeder in the UK. That is not too hard, because the agricultural landscape is dominated by multinationals. I am also vice-chairman of the International Maize and Wheat Improvement Centre board of trustees in Mexico. This is the largest publicly funded wheat programme on the planet, breeding for 200 million hectares. To put that into context, that is 100 times the size of the UK. Their focus is primarily on the developing world.
Professor Napier: Hello. My name is Johnathan Napier. I am a project leader at Rothamsted Research. I am a plant biotechnologist. I have a degree—PhD and DSc—from the University of Nottingham. Rothamsted is a publicly funded research institute. I am passionate about using basic research for public good and translation. I am very keen to see the research move beyond just discovery. I ran the first gene edited field trials in the UK in 2018. I have run GM field trials at Rothamsted since 2011 or 2012, and I am looking forward to talking with you.
Professor Halford: I am Nigel Halford. I am also at Rothamsted Research. I have been there a long time—all through the biotech period. In fact, I was involved in GM wheat trials in Bristol in the 1990s. Like Johnathan, I am very passionate about taking our research through to products that are actually going to help British farming, agriculture and consumers. I am currently running a gene edited wheat field trial at Rothamsted. We are looking at reducing the acrylamide content of wheat products, so it is a food safety target.
Jo Churchill
Q
From the point of view of small and medium-sized enterprises, do you think this Bill will help smaller players to have some access to market, or would you like to see this Bill enable smaller breeders, such as yourself, to have access to these technologies?
William Angus: That is a good question. I have worked for a large multinational company. I was interested to hear both Johnathan and Nigel talk passionately about public good—that is what I do. When I was at the PBI this was part of your culture and it became part of my culture when I was at Limagrain.
I love the entrepreneurial spirit that we have in the UK. We started off this, which may be considered by some to be a slight mission of madness, but I had the opportunity to do it. We started in my lounge, then we moved to the greenhouse and then the garage, and now we have built up quite a significant activity.
I am worried about perhaps an agenda that this could be dominated by large multinationals, although one of the joys of wheat-breeding globally over the last 100-plus years has been the freedom to exchange germplasm. As soon as we start putting constraints on that, as soon as we start having people talking about ownership of genes and ownership of genetic material, or licensing genes that are already in the public domain, it starts to fill me with a great sense of foreboding.
Also, being on the CIMMYT board, I am really concerned and very passionate about the smallholder farmers that we have around the world. It has changed my life being on CIMMYT, in that it opened my eyes to the fact that there are millions and millions of people in very dire circumstances. Many people do not realise that the vast majority of farmers in the world are women.
So, yes, I am concerned about that and I would like to see some mechanisms whereby the freedom that currently exists for small companies, or individuals, to start up is not diminished. Therefore, I hope that some protection will be put in place.
Johnathan and Nigel may agree or disagree, but what we have in the UK is that, if you go back 40 years ago, we had a publicly dominating plant-feeding activity in the PBI. We have a really mature situation now. Globally, we are probably the best, and I have seen a lot around the world, of having these public-private partnerships. These guys at Rothamsted, or the John Innes Centre, or whatever, cannot take it to the market and we have a wonderful relationship with them, in that they do the fundamental research and then we, as the plant breeders, translate it into the field. And I include the multinationals in that.
We have a very mature situation and we must make sure that, whatever comes out of this Bill, that relationship is not damaged in any way and continues.
Jo Churchill
Q
However, I will direct my next question to both professors, in the hope that you both cover it to a degree. You have both expressed a passion, and have longevity about looking at this issue, and I think it was Professor Halford who said that he was involved in the GM trials in the ’90s. Can you please help us to understand how far we have come and say what benefits we should try to capture through this Bill in order to drive things forward?
Professor Halford: Any target you can think of for plant breeding—whether it is something that aids farmers, such as nitrogen-use efficiency or simplifying weed control, climate resilience, which is an urgent problem that we have to address in agriculture, or the kind of things that we are working on, benefits to consumers—gene editing can play a role in it. It is not sweeping anything else aside, but it certainly enables you to do some things that other methods in plant breeding do not allow you to do. That is what we are talking about.
Professor Napier: Nigel and I are veterans of the GM of the ’90s, the problems that emerged from that and the hiatus of seeing none of our research translated for a decade. Then, at Rothamsted, we restarted GM field trials in 2012, just because we realised that there was this urgent need to translate the research. The UK has a fantastic reputation for doing basic plant sciences, making lots of fantastic discoveries in labs, but that is no good to feed people or to solve the challenges of climate change and food security. You cannot eat promise; you really need a product.
The reason I am in agriculture is that it is the ultimate scalable solution: once you demonstrate that you can grow something in one field, you can grow it in a million fields. But until you have actually done it in the first field, you do not know whether the technology works. That is the exciting thing that has already changed in the regulation in the past few months—it is easier to do experimental gene edited field trials. Nigel and I are doing those at Rothamsted under the new regulations, and that is great, that is enabling. That is what we need.
We want to enable the technology to advance, which is not to say that we ignore the importance of safety and all those other things. On one level, it goes without saying that those are important, but it should not go without saying—you have to say that those are of paramount importance. What we want is enabling regulation. I am not totally sure I have answered your question, but it gives you the idea.
Jo Churchill
Q
Professor Napier: That is exactly right. Even if you look at the situation in the US, which is imagined to be the most tolerant and enabling of regulatory environments for GM, for example, it still costs probably $10 million to deregulate a crop. That is an utter barrier to entry to any small or medium-sized enterprise. The reason why the market is dominated by the large corporations is that they are the only people who can afford to pay those costs. If the barrier to entry is lower, basically you make it much more open to the more entrepreneurial, smaller, nimbler but less deep-pocketed organisations.
Professor Halford: The GM revolution is now a generation old. It is a 20th-century technology. We see varieties in the Americas and Asia with multiple input traits, output traits, insect resistance, herbicide tolerance, high lysine with a cherry on the top. None of that is available here—absolutely nothing, not a single GM crop plant grown commercially in the UK. We have completely missed the boat on that one, and it is really important that we do not miss the next boat.
We will have to go some way to persuade plant breeding companies, biotechnology companies, that there is a market in the UK. Currently, I can tell you, nobody is thinking about developing a GM or GE commercial crop for the UK or Europe. We will have to have regulation in place that gives breeders confidence that when they get their product to market, they can actually sell it. If my wheat all pans out, it works really well and I hand it to breeders to incorporate into their breeding programmes, we are still talking probably five to 10 years before we could possibly see anything on the market. That is a lot of work and investment. So farmers need to be confident that, at the end of that, they have a market.
The Chair
I remind people that we have until 3.15 pm for this session. A couple of Members have caught my eye. I will start with Daniel Zeichner.
The Chair
Thank you, William. We have less than a minute left. I know the Minister wants a quick question—it is less than a minute for your question and the answer.
Jo Churchill
Q
Professor Napier: Yes.
Professor Halford: Yes.
William Angus: Yes.
Jo Churchill
This feels like “Britain’s Got Talent”. There we go; we have finished before 3.15 pm.
The Chair
That brings this session to an end. I thank all our contributors for a really informative session.
Examination of Witnesses
Roger Kerr, Steven Jacobs, Joanna Lewis and Christopher Atkinson gave evidence.
The Chair
We will now hear oral evidence from Roger Kerr, chief executive, and Steven Jacobs, business development manager, both of Organic Farmers & Growers, and from Joanna Lewis, policy and strategy director, and Christopher Atkinson, head of standards, both of the Soil Association. All the witnesses are with us in person. We have until 3.50 pm for the session. Will each of you in turn introduce yourself for the record, and then we will come to questions?
Roger Kerr: My name is Roger Kerr. I am chief executive of Organic Famers & Growers. I am also a trustee of the Organic Research Centre, which is an independent organic research organisation. I am also a director of the Organic Trade Board.
Steven Jacobs: I am Steven Jacobs. I am the business development manager for Organic Farmers & Growers.
Joanna Lewis: I am Joanna Lewis. I am the policy and strategy director for the Soil Association and a trustee at the Food Ethics Council and at Sustain, the alliance for food and farming.
Christopher Atkinson: Hello. I am Chris Atkinson. I am head of standards at the Soil Association charity. I am also an elected board member of IFOAM Organics Europe, our European umbrella organisation.
Jo Churchill
Q
Christopher Atkinson: Organic is a regulated activity, so the requirements for organic production, including separation and segregation, are laid out in law. In the UK, that is currently a retained European regulation, No. 834. That mandates an inspection and certification system based on international norms for product certification. The way in which producers who are under the control system specified in the regulation notify their activity and interaction with independent third-party certifiers, such as Organic Famers & Gowers and the Soil Association, is described in that regulation.
It is very much a farm-to-fork regulation: it covers all parts of the production process, from the farm, beyond the farm gate, right through to the point of sale. There is complete traceability, which is overseen by the certification bodies and maintained through record keeping and some elements of testing and checking, which are carried out both by those who are subject to the regulation and by the certification bodies that oversee their activity.
Roger Kerr: The question was also about the risk of GM to the supply chain.
Christopher Atkinson: Yes. At the moment, there is prohibition of GMOs in organic production, and organic producers rely on the current labelling regime to verify and identify freedom from GM. There is also a testing regime based on detection thresholds for GM specified in the legislation, and there are duties both on the producers and on the certification bodies to apply those requirements.
Jo Churchill
Q
Joanna Lewis: Your mention of PRRS offers a good way to explain why the global organic movement currently does not support the genetic engineering approach. That movement is very much founded on the principle that you harness natural processes to stop pest and disease problems arising in the first place. For instance, PRRS is widely accepted to be a disease that arises from industrial farming systems as a result of overcrowding. The crucial thing is to make sure that there is a public interest test at the heart of the Bill, and that is what we are calling for.
We noted that the Regulatory Policy Committee has raised a red flag about the impact assessment—I am sure that it has been discussed before. We found that the impact assessment had overlooked three crucial areas: first, clearly, the freedom of choice for citizens; secondly, the needs and interests of organic agroecological farmers and growers, who have a key role to play in the Government’s ambitions for a sustainable farming transition; and, thirdly, the impact on the Government’s ability to achieve their own really important legal biodiversity and climate targets, and to address their professed concern about animal welfare and their desire to improve those welfare standards.
One does not need to doubt the good intentions of the research institutions that are involved in the research, but there are strong commercial drivers at play here. It is no accident that current and recent developments on gene editing of crops relates overwhelmingly to herbicide resistance. When you have four companies controlling 60% of the global seed market and two of them, Bayer-Monsanto and ChemChina, which owns Syngenta, account for more than half the agrichemical market, it is no accident that there is that commercial bias.
When it comes to the interests of farm animals, the Nuffield Council on Bioethics held a public dialogue on gene editing and farmed animals. The concern expressed by the public, now backed by the support of the Biotechnology and Biological Sciences Research Council, and Sciencewise—I am on the oversight group for that dialogue—was clearly centred not so much on the distinctions between gene editing and conventional breeding, but on the fact that the direction of travel for conventional breeding had been to prioritise traits that came at the expense of animal welfare and which facilitated the keeping of animals in inhumane industrial farming systems. The concern was that gene editing might accelerate that trend.
That brings us back to the question of where the public interest test is that could allow the Government to do more than just presuppose and gamble on the benefits of this for climate, nature and health. Norway has developed a gene technology Act, which places that public interest test at its heart. I do not know if that has been discussed yet, but there is a test that requires evidence of community benefit and support for sustainable development, so we would like to see that considered in the deliberation of this Bill.
Steven Jacobs: Just to pick up on where we stand as an organic control body, our role is to maintain integrity through the whole chain of custody, from farm to fork and from seed to shelf. You cannot necessarily tell that a bottle of milk is organic by testing it—actually, there could be tests for that. You can tell a bottle of milk is organic because we have inspected every stage of the process. According to our licensees—and we license more than half the organic land in this country—that is not onerous. They already do various certifications, such as Red Tractor. Our inspectors will be able to do two, three or four of those in one visit. Asking the same question can generate two, three or four certification requirements.
The situation we have is one where there is an established market. In this country, it is worth around £3 billion. Globally, it is worth around $100 billion. It has been going for 60 or 70 years. The regulatory regime has been in existence since the early ’90s. That integrity is accepted in the marketplace and is being bought by shoppers. In the consultation, something like 85% of respondents said it was not that they necessarily objected to gene editing, but they would like to see existing regulatory frameworks upheld. We work in a regulatory framework. We have ISO standards. We are audited by a Government-approved auditor every year. That is how we ensure that that integrity is maintained. For us, those customers have said they do not want GE or GM.
Jo Churchill
Right, okay. I am not sure that I entirely understand why you feel it would be any different with GE, which is a completely different technique—with all due respect—from GM. If I could tease out that animal welfare point, you are predicating your argument on the idea that everything is detrimental on a welfare front. Surely the eradication of avian flu—particularly as we have had the challenge in the last year—would be beneficial to free-range birds as well. I am keen that the rest of the Committee has its chance to contribute, though.
Daniel Zeichner
Q
Roger Kerr: From an organic regulatory basis, as Chris has already indicated, GE is still defined as GM. We need to be much clearer about what GE is being defined as, and we still do not have that clarity. As things stand, it is not allowed within the organic regulation, so the risk is where there is a lack of co-existence measures in place, which means that organic crops are contaminated. Organic consumers make these purchasing decisions because they believe they are avoiding GM, and that is a right they should have.
By not having robust co-existence measures in place, we are obviously putting our consumers at risk, because they are purchasing organic products on the basis that they do not believe they are consuming GM. It is a personal choice—I am not saying that you should not—and the organic sector is not saying per se that we should not have genetic editing. What we are saying is that it is incompatible with organic. Organic is out there, and there is a market for it, as Steve has clearly stated. There is a significant opportunity, both domestically and internationally, for the UK organic sector.
We should protect the organic sector, and there should be some visibility in terms of GE—where it is being grown, what is being grown and what the potential risks associated with that are for the organic sector—so we can ensure that the organic sector remains free from GM or GE, as it is at the moment. There is concern that if we are looking to provide consumers with the choice of having GE or not, we will end up with quite a significant cost within the supply chain to ensure co-existence, in terms of space and time, between GM and non-GM. This is not organic per se; it is just GM and non-GM. We will then have to have extra storage, more vehicle movements and a much higher level of testing. There are concerns that, without real clarity about what is going on and where the potential points of contamination arise, a significant cost will be borne by the food sector, which is already under significant pressure.
Joanna Lewis: I understand that you are addressing us as the organic industry and the organic sector, but I just want to reiterate that the Soil Association is a charity of 70 years’ standing that represents all citizens, farmers, growers and scientists who want to see a mainstream transition to agroecological farming and regenerative farming for climate, nature and health.
The response to the consultation on the Bill—85% of people and businesses were opposed—reflects a deeper unease not just about the safety issues and technicalities around the distinction between gene editing and GMOs. That is what I was trying to bring through with reference to the Nuffield Council on Bioethics’s public dialogue. It is really important to emphasise the very legitimate public concerns about the fact that breeding as a whole—plant and animal breeding—has been on an unhelpful trajectory that is not up to the challenge of the Government’s goals on sustainable farming transition. We therefore need to ensure that we are not accelerating that trend through carte blanche deregulation.
There is an opportunity to put good governance at the heart of this Bill, set that public interest test, and ensure full supply chain traceability, transparency and labelling for citizens who want and deserve the right to choose whether this is the solution for them. I would not want it narrowed down to saying we are representing an economic sector. This is a broader movement, and it is very much one for mainstream transition.
The Chair
Q
Dr Harrison: I am Richard Harrison and I am director of crop research at NIAB. NIAB is an independent research organisation based around the country. It receives both public and private funding, and it sits in the area of strategic and translational research in crops. My role in NIAB is as the director of Cambridge Crop Research, which encompasses most of the arable crop research we do in the organisation. That include genetics, biotechnology and some of the statutory work that we deliver in seed certification and variety valuation for the Animal and Plant Health Agency on behalf of DEFRA. My own research is in the area of plant-microbe interactions in complex trait genetics. Most of that work has been done over the past 10 years in horticultural crops—strawberries, cherries, raspberries and other tasty things—where my group have worked on disease resistance but also developed and implemented gene editing technologies in those crops.
Professor Oldroyd: I am Professor Giles Oldroyd. I am professor of crop sciences at the University of Cambridge. I am a fellow of the Royal Society and I am director of the Crop Science Centre, which is an alliance between the University of Cambridge and NIAB. I am the University of Cambridge component of that alliance. My research focuses on how we improve the sustainability of farming systems, with a particular focus on removing the need for inorganic fertilisers from farming. I work on driving sustainability in developed-world farming, but also for smallholder farmers in sub-Saharan Africa. I get most of my funding from the Bill and Melinda Gates Foundation. I currently have a field trial ongoing in Cambridge that uses a combination of genetically modified lines as well as genetically edited lines.
Jo Churchill
Q
Professor Oldroyd: I think that the current Bill would be truly transformative in our ability to see impact from the foundational research that happens in many of our universities around the country. The UK is a world leader in plant sciences. It has been very frustrating for plant scientists to struggle to see impact from their research because of the restrictions that are placed on the release of potential products from their work.
I believe that gene editing is equivalent to what you can achieve from conventional natural processes, but the level of precision that it provides allows us to do things in a way that we could not—or found it difficult to do—when restricted to only what is available in the natural diversity of that crop. It really does allow us to move things from the lab to the field to the consumer in a manner that is much more straightforward, to apply the phenomenal knowledge that we have developed in plant research in the UK over the last 30 or 40 years, and really to drive what I believe is a crucial transformation in food production. We have phenomenal challenges facing us: we have to feed a growing population, drive sustainability and cope with climate change, all over the next 30 years. That is not easy and we cannot do it with our hands tied behind our backs.
Dr Harrison: I could not agree more with that synopsis. One of the major strengths in the UK is our fundamental research base. Over the past 30 years, we really have understood at a deep level how genes function—in plants and in animals—and the ability not only to capture what is there in nature through conventional breeding, but to use technologies that allow the directed introduction of mutations that could occur naturally but are not necessarily present or are not in the right pre-adapted germplasm. Bringing those into the gene pool and using them for crop and animal improvement is, as Giles says, transformative to our abilities to address the major challenges that we face in food production and the sustainability of food production.
Jo Churchill
Q
Professor Oldroyd: There are currently very tight restrictions on validating the health and safety of GM products. For products produced by conventional breeding, we also have tests with regards to their performance in the environment, their performance relative to other varieties and their health. We have a robust regulatory framework in place that addresses the safety of the consumer, and it has served us well over many decades. I cannot think of an example where we can say, “Okay, this line has caused genuine risk to human health,” and that is because of the regulatory framework that exists.
Daniel Zeichner
Q
My questions are about public confidence. We know that this has been a vexed debate over many years. There is fantastic science being done in Cambridge, but it often strikes me that the wider public have very little idea about it; that is hardly a unique issue there. Do you think there are sufficient measures in the Bill to secure the public confidence that is needed? If not, what extra could be put in to secure that?
Dr Harrison: The key point is proportionality. In all the preamble to the Bill, it is suggested that there is a proportionate response to how the technology is regulated. What we must never forget about gene editing and the scope of the types of changes that can be introduced is that they are indistinguishable from nature, so fundamentally we are not doing anything that could not happen or arise through natural processes.
The level and proportionality of the regulation of, and the transparency of, those products is important, and it is important that the public are aware, which I suppose is why there are systems in the Bill to register intent to put into the existing system gene edited products, but I do not think we need to stretch much beyond that. We have, as Bill Angus said, very well established regulatory frameworks in which to evaluate the performance of crops. We have the DUS system—distinctiveness, uniformity and stability—and we have the value for cultivatable use system. They have shown over many years that when varieties are put on the market, they are safe. The legislation that exists beyond that gives any country the right, if they find a problem with a variety, to remove that from what is the common catalogue in the EU, or, in our case, from our national list. As long as the proportionality is adhered to, the Bill is appropriate.
Professor Oldroyd: There are a lot of studies that have looked at the general public’s position on biotechnology. There are really only a few at either extreme—who absolutely support it outright or who are very scared of it. Most of the general public are looking to people like me—to scientists—and to the regulatory framework to define what is safe to consume.
Within precision breeding, as is intrinsic to the Bill, is the fact that these are events that could happen by exactly the same natural diversity and so already could be introduced, theoretically, through a conventional breeding process. One of the issues is that some—in particular, those on the previous panel—have taken as a presumption that anything that is biotechnology is inherently dangerous, and that is not correct. It is not correct to say that just because it is being developed by this mechanism there is an inherent danger in that approach. That is the erroneous position to take when comparing with conventional breeding.
We use many varieties that have been generated by mutagenesis breeding, by double haploid production. These are conventional breeding approaches. There is very little about gene editing that is different from that in the end product; it is just how you get to that event.
Jo Churchill
Q
The Chair
May I jump in here? We have about four and a half minutes left, and Daniel Zeichner wants to ask a question as well.
Professor Oldroyd: A lot of eyes are focused on this country at the moment, with regard to how we approach this. We have to recognise that we influence quite a bit. Countries in sub-Saharan Africa are absolutely looking to Europe, to the UK, for leadership on this. Our position will influence internationally how these technologies are legislated for. Certainly, we have a lot. I am excited about the potential to drive up food production for smallholders, as well as the sustainability of farming practices here in the UK. The opportunities are immense. Definitely, having this, the ability to use gene editing, will facilitate that delivery both to smallholder farmers and to UK farmers.
The Bill and Melinda Gates Foundation is definitely paying attention to what is happening here in the UK. With regard to additional investment, this Bill opens up opportunities for the UK. We are already a leader—we really are a leader in agricultural research—and I think it will position us even more greatly to be spearheading the impact of all that agricultural research.
Dr Harrison: I, too, see a big opportunity for the UK not only to lead, but to garner additional investment. At NIAB, where we operate in both the private and public sectors, we have seen on both sides a big increase in the attention given to the services we offer to industry and academia for crop transformation and gene editing. I definitely think there is an opportunity here. In the kind of ecosystems that you see around major university cities such as Cambridge, there are a lot of start-ups that are very much trying to bridge the gap between the need to use crop science to transform food and farming to be sustainable, and the use of new technologies. A definite opportunity.
The Chair
We will now hear oral evidence from Sam Brooke, chief executive of the British Society of Plant Breeders, who will be giving evidence in person. We have until 4.50 pm for this session. Before we open the questions with the Minister, could you please introduce yourself?
Sam Brooke: Good afternoon, everyone. I am Sam Brooke, and I represent the British Society of Plant Breeders, which is a not-for-profit society. We currently represent 80 members of the plant breeding sector, which is virtually 100% of the plant breeding industry in the UK. As you can imagine, because we have 80 members, we range from one-man bands and SMEs to multinational breeders, so we have a very good coverage of the breeding industry in the UK. Our main aim is to continue to promote plant breeding, the importance of genetics, and the importance of seed and where it fits into the scheme of things.
Jo Churchill
Q
Sam Brooke: From our perspective and that of our members, the legislation offers huge opportunities. It will definitely open up investment in the UK for plant breeders. When the European Court of Justice ruled in 2018 to legislate precision breeding techniques as genetically modified organisms, around 70% of our members classed as SMEs ceased investment in those new technologies because of the expense and political uncertainty around being able to bring those products to market. From our point of view, it is critical that these new techniques are now available and can be utilised.
We believe that the legislation will naturally bring the cost of those new techniques down, giving a broader range of our members greater access. As I have mentioned, we have guys who are literally one-man bands, who are breeding locally in the Cambridgeshire area where we are based, and we also have the bigger multinational companies. You have mentioned being fair and equitable: breeders have already established a network of trait licensing platforms, which we see working very well across the UK and Europe. A very successful vegetable trait licensing platform is already established, and an agricultural trait licensing platform is being established as we speak. That is a fantastic way of ensuring that those traits are available across all breeders and all entities, of all shapes and sizes, which is great, because it means they have access to broader diversity, more technologies and more traits. That is really important.
Jo Churchill
Q
Sam Brooke: As a whole, the BSPB is incredibly supportive of the Bill and what it is trying to achieve. Our main concern would be around clause 3 and a risk assessment around food and feed. All the scientific evidence would show that there is no greater risk in using these technologies than in using what we currently are in conventional or traditional breeding—or whatever we want to call it—so I feel that there is no reason for that extra risk assessment step. We are very concerned that that could act as a blocker to early stage research and development.
Daniel Zeichner
Q
The key issue is getting the balance right between reassuring the public and following the science. However, to many of us, this Bill looks very thin on the “reassuring the public” side—so much so that, despite the FSA and its polling showing that the public would really like more information, as the Bill stands, that is not the way it will be. How convinced are you that the issue of public confidence will be resolved in favour of the science?
Sam Brooke: Having lived and breathed plant breeding for just over 20 years, I think we should have shouted more, and earlier, about how regulated the industry is, both at plant-breeding and seed level. We have a rigorous testing system in the national list process. Each variety undergoes at least two years of testing before it comes to the market. Every variety must be on that UK national list before it can go into sale. All that is underpinned, obviously, by laws on food safety, novel foods, and so on. We have this incredible history of safety of plant breeding in the UK, and of bringing those products into the market in a safe, sensible and secure way.
On top of the registration process, we also have seed marketing legislation, which really protects the user. Naturally, it protects the consumer in that it ensures that all seeds that go out into the market meet a common and prescribed standard. I think that is really important, and it is probably our fault as breeders that we have not shouted in the past about how legislated the process of producing new varieties and seeds actually is. That is what we need to go out and talk about, and tell the consumers. I am a consumer—we are all consumers—and I think, had consumers had more information and knowledge about how regulated varieties and seeds already are, we might already be a step closer to having that absolute trust.
The Chair
We will now hear evidence from Dr Alan Tinch, vice-president of genetics at the Centre for Aquaculture Technologies. He is appearing via Zoom, as we can all see, and we have about 20 minutes for this session. Could the witness please introduce himself? Thank you also for joining a little bit earlier.
Dr Tinch: No problem. I joined five minutes early just to be prepared. My name is Alan Tinch. I work for the Centre for Aquaculture Technologies, which is a company involved in developing technologies for use in fish breeding and aquaculture. I work on projects in genetics, genomics and gene editing. In terms of my background, I am a geneticist. I graduated from the University of Edinburgh and Roslin Institute in Scotland many years ago. I have worked on a number of different species, both terrestrial and aquatic. Throughout my career, I have worked on genetics, genetic development of breeding programmes and developing new systems for improvement of livestock.
Jo Churchill
Q
Dr Tinch: That is an interesting question. I think all livestock breeding is now very much international, so it is difficult for small companies based in one country to operate successfully. There are a number of large international operators in genetics. In aquaculture in particular, we are not as far down the development of the species as some of the terrestrial species. We have been farming and breeding fish for about 40 to 50 years, so we are domesticating many of the species already. We are working hard to improve things such as disease resistance. There is good evidence, and we have seen very good examples, of genes that can be used to improve health and welfare of fish—particularly with Atlantic salmon, where a Scottish group identified a gene that accounted for over 80% of the variation of disease resistance. That was bred into the salmon populations and is now in most farmed salmon populations, making them resistant to the infectious pancreatic necrosis virus.
I see the implementation of gene editing allowing us to do similar things. Without having to go into the field, if you like, and look for animals that are carrying favourable mutations, we are able to identify genes that affect things like disease resistance, make targeted changes in those genes and make fish resistant as a result. I think that is a very positive way of taking breeding forward. It is not the only tool in the toolbox, but it certainly allows us to do some very interesting and valuable things for the health and welfare of the animals we farm.
Daniel Zeichner
Q
Dr Tinch: That is a tough question. The association between improving the ability of animals to perform and changing disease resistance, and the idea that that means we are going to increase stocking density and make welfare worse, is very simplistic, and it is not as simple as that. That is not the way farmers tend to operate, and it is not the way that breeders operate practically. That argument is raised quite often as being a reason not to improve farm animals, but it is not like that.
We should use the technologies that we have to improve animals. We are putting them in a farming environment that is different from the environment they evolved in. We have to adapt them, using genetics, to the farming environment, and that is what we aim to do. We aim to improve health, welfare and the sustainability of the animals from an economic point of view and an ecological point of view, and we use a number of different methods to take that forward. The tool is genetics, and gene editing is the next step forward in our ability to change different things. We should look at how we aim to improve animals in a constructive and welfare-driven way.
On the trade issues, if the legislation put us in a position where we were restricted in the use of the technology, we would be faced with the problem of people farming gene edited animals in other countries, and we would not be as competitive. We are already seeing gene edited animals being farmed in Japan, for example, and there is very permissive legislation in places such as Canada and Australia. I think those countries will be the first to bring in this technology. I see that coming first in some of the economic traits, and we will face competition as a result—maybe not in the species that they are planning and gene editing at the moment, but as it comes through the system in these areas, we will see our industries being uncompetitive in their performance.
Genetic Technology (Precision Breeding) Bill (First sitting)
Jo Churchill ExcerptsTuesday 28th June 2022
(2 years, 5 months ago)
Public Bill CommitteesRead Full debate Genetic Technology (Precision Breeding) Act 2023 View all Genetic Technology (Precision Breeding) Act 2023 Debates Read Hansard Text Read Debate Ministerial Extracts Amendment Paper: Public Bill Committee Amendments as at 28 June 2022 - (28 Jun 2022)
The Chair
We will now hear evidence from David Exwood, vice-president, and Dr Helen Ferrier, chief science and regulatory affairs adviser, both of the National Farmers Union. Thank you for coming this morning. I can see that you are both there—both our witnesses are appearing via Zoom.
Before calling the Minister to ask a question, I remind all Members that questions should be limited to matters within the scope of the Bill. We must also stick to the timings in the programme motion that the Committee has agreed. This session will finish at 10.10 am. With all witnesses, I will first call the Minister and then the shadow Minister, before opening up to questions from others in the Committee.
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
Q
David Exwood: I think farmers welcome this Bill, because of the possibilities it offers. I am really clear that the big gains, the big changes, in farming are all around breeding. Yes, there are gains in productivity around my machinery, but really the exciting things in the future are all around breeding and the possibilities that brings, and the Bill will help with that.
For all my farming career, I have used pesticides as part of the process. I am very happy about that, but we now genuinely have an opportunity to produce as much food as we do now but with much less impact. So I think farmers welcome the Bill, which opens a world of possibilities and addresses the challenges we face at the moment. There is so much pressure on land use, and the ability to produce the same amount of food as we do now but with less environmental impact and more sustainably is something all farmers welcome.
Dr Ferrier: Ultimately, the market will decide whether this technology is adopted here, but I think that, before that happens, the regulatory system and the legislative process will decide whether farmers and growers have access. The technology is clearly being developed around the world, and regulatory processes are being reviewed and put in place around the world. Farmers and growers are not going to be able to access the products of the technology and realise those benefits that David has talked about if companies are discouraged or regulation is not enabling. So the impact of the Bill depends on how well it is written and whether it will be proportionate and fit for purpose and will therefore encourage the investment of breeding companies that then enables farmers to adopt the products of the technology.
Jo Churchill
I have other questions, but I would like this process to be collegiate, so perhaps we should go to others, because they may ask the same questions as I will.
Jo Churchill
Q
Professor Henderson: Yes, I would. I think I can reassure the Committee on both those questions. I have been involved since the very early stages of the preparation of this Bill in consulting widely with the scientific community, advising Ministers and officials in my Department and others, and talking to stakeholder groups about the science and its implications. The Bill has taken into account the science and the most expert views of it in a very diverse way. I am personally content that it is fit for purpose and will ensure the continued safety of the environment and food.
Daniel Zeichner
Q
Professor Henderson: There is an interesting question about how far deregulation into genetic technologies ought to go in one step. Some groups of scientists would certainly favour a model in which you relax the regulation much more widely and base all the outcomes on the traits that are produced through that technology—the outcome in the product—rather than having any view about the technology or the process by which the product is made. That is certainly a view that some scientists would hold.
The view of Government—this has played out in a number of stakeholder groups— has been that moving more cautiously to deregulate or lower the regulation of some aspects of genetic technologies first is a cautious and stepwise way to move. That takes account of the science, enables us to be aware of the issues as they arise, and most importantly builds the confidence of the public as those technologies are used more widely in food production. That is the justification for moving first into the use of technologies only to mimic breeding processes through precision breeding, as described in the Bill.
There is a difficulty in describing the limits of what is possible with breeding. It is clear that some things that are possible—we know they are possible because we have done them—are very similar to things that have been done, and they are therefore clearly in scope. There are other examples that are clearly not possible through breeding. In between those, there is something of a grey area. There is now detailed advice from an expert group—the Advisory Committee on Releases to the Environment—that lays out the definition of the circumstances in which something would be considered possible through breeding, and therefore would be considered a precision bred organism, to define the line within that grey area.
You also asked about exogenous material, by which I take it you mean material from another species. That sort of material can occur entirely naturally, and it can occur during breeding processes as well, but in general it does not lead to any functional change or any phenotypic change. The Bill is designed not to allow exogenous material, if it has any functional or phenotypic outcome in the product. In that way, it does mimic the action of traditional breeding. I hope that answers your question.
Jo Churchill
Perhaps we can ask Professor Henderson to dial off and dial back. Let us see if we can retrieve him.
The Chair
You are back, Professor Henderson. We move on to the SNP spokesperson, Deidre Brock.
Jo Churchill
I understand, Gideon, that you are on a visit. May I suggest, with the Committee’s indulgence, that we slot you in on Thursday, if people are agreeable and you have the time? Your evidence is both welcome and vital, and we would like to hear from you.
Professor Henderson: Again, I can only apologise for the bad wi-fi I have here. I would be happy to come back to you at any time that suits the Committee.
The Chair
We have 10 minutes left in this session, so let us have one more try. If that is unsuccessful, then, with my co-Chair, we can consider changing the programme motion. We have agreed a programme motion so it would have to be formally changed. Will you ask the question again, Ruth?
The Chair
We now come to Professor Robin May. We have until 11 am, so we have gained five minutes. Thank you for giving us your time and expertise this morning. Could you briefly introduce yourself?
Professor May: Certainly. I am Robin May, chief scientific adviser at the Food Standards Agency and a professor of infectious disease at the University of Birmingham.
Jo Churchill
Q
Professor May: There are probably two answers to why this is necessary. Currently, precision bred foods and feeds will be encapsulated within the existing GM framework. If they are moving out of that framework, it is important to be sure that those products are safe. The key difference here with traditional breeding is one of pace. The entire point of this technology is to do things that could have been achieved through traditional breeding, but much faster. It is important that we have safety checks along that pathway.
On your question about balance, I think the key balance to strike here is between supporting innovation and ensuring safety. At the moment, our thinking around this is to have a two-streamed process for regulation, where there is a very light-touch process for anything where there is unlikely to be a substantive change in the food and more scrutiny of anything where the final food product is different. I think that is quite appropriate for this blend of technology.
Daniel Zeichner
Q
Professor May: We have undertaken quite a lot of consumer research in this area, as have many others. There are various take-home messages from that. The first is that there has been a perceptible shift in public views over the last 10 or 20 years, and there has been more interest in the potential benefits of this technology. That is mirrored by a really strong view that the public want some level of regulation and safeguards in this and other genetic technologies.
Specifically around labelling, there is a very strong majority of the public that we have polled, and that others have seen, who would like labelling of these products. There is some difference of views about what that labelling should entail, but there is a strong feeling around it. From an FSA perspective, we would in principle support that, because we stand very strongly for transparency. The problem, sitting here as a scientist, is that this is not really achievable for this particular group of foods, because the entire nature of the precision breeding legislation is to consider things that could have been produced traditionally.
Consequently, you may end up in the future with two apples, for instance, and one was produced by precision breeding that involves gene editing and the other was produced by traditional methods. It would be scientifically impossible—at least, at the moment—to tell those two apart.
Then, from my perspective, my view is that a label that is not enforceable and that might be misleading is actually worse than no label at all, because you then start to spread doubt about the validity of other labels in the food system: allergen labels, nutritional labels. While in principle I think labelling would be a good thing, the fact that we cannot enforce it makes me feel that this is not appropriate for this type of food.
Daniel Zeichner
Q
Professor May: That is correct, yes.
Jo Churchill
Q
Professor May: There is a range of approaches across the world. It is probably true to say that no two countries have exactly the same approach at the moment. Perhaps I may give some examples.
At one end of the scale, you would have the current approach in the European Union, where all genetic modification, even genome editing that would fall within precision breeding, is regulated as GM and goes through a full risk assessment, often involving toxicology and quite a lot of analytics. At the other end of the scale, you have the US, for example, which has a default setting: if it is similar to something that was traditionally bred, there is no regulation.
Perhaps in between, the Canadian example is an interesting one. In Canada, they regulate the product and not the technology that has created it. They ask—let us go for an apple—“If you have created this apple, is it different from an apple I can buy currently?” If it is not different, it is not a novel food and it is not regulated; if it is different, it is a novel food and it gets assessed, regardless of how you made it. If I made that apple by precision breeding and it is different, it would be regulated; if I made it by crossing two apples in my orchard and creating a new apple tree that was different, it would still be regulated through that process. Scientifically, that is a very valid approach, but it means that you encompass within it all of traditional breeding and all the things that are done but not regulated in that way in this country.
The Chair
Good morning, Professor Dunwell, and thank you for giving us your time. We will finish this session at 11.25 am. Will you introduce yourself briefly?
Professor Dunwell: I am Jim Dunwell, professor of plant biotechnology at the University of Reading. I am also chair of ACRE, the Advisory Committee on Releases to the Environment, and have been for the past nearly three years.
Jo Churchill
Q
Professor Dunwell: Absolutely not. Some people suggest that speed, when it is applied in this kind of science, somehow has an intrinsic risk attached to it. That is slightly strange, as in most areas of science and innovation we are striving towards efficiency, whether it be in producing better vaccines or better batteries for electric cars. We are in a competitive world, and we can be sure that, as a nation and a scientific group, we are up against people who are having the same discussions elsewhere. If you are a plant breeder—not that it is a particularly profitable business—the ones who are successful are those who make genetic gains more efficiently and more quickly. Ever since we have known how genes control plant development, there have been advances in plant breeding to try to go through generations more quickly, so that people can capture, create and select genetic variation more quickly, and get their products to market more quickly. This is another element in that, which allows further increase in efficiency. Therefore, I have no intrinsic doubt about it.
Jo Churchill
Q
Professor Dunwell: No, not at all. It is something that ACRE as a group has had discussions about in the past decade, saying that the traditional methods of regulation were not really keeping pace with the change in the scientific information. Some 10 years ago nearly, we produced a report leading the way on that. Some of those issues have now fed through into the present proposal for regulation. Something you do with gene editing is to make slightly different, smaller genetic changes—that is the precision—enabling you to take a good variety and make it slightly better, just by making an existing change. In the past, you would have to put together different hybrid combinations. You would then have to go through massive selections of the best progeny, and that takes time. In terms of breeding a new variety, it may take five, eight or 10 years. That, now, can be cut back substantially.
Jo Churchill
Q
Professor Dunwell: I think it is very appropriate. Obviously, it follows on from our removal from the EU. As for the legal case that created this, I suppose, concern, most scientists in the UK and the EU realised that it was a sort of perverse judgment when it comes to traditional so-called mutagenesis, where you apply chemicals or radiation—that is considered a traditional method and has been for 50 years. If you go back to the ’50s, there was a society of atomic gardening. That was when atomic energy was “good”. There was a very popular and interesting character who set up the atomic gardening group. She used to demonstrate her plants at Chelsea; she used to have dinner parties and carry round irradiated peanuts to offer to people. It was considered a good thing, but it was a complete unknown. But there was no evidence of any problems relating to it. We can now make particular small genetic changes in a much more precise way, and I think it is a good time for the UK to take a lead and apply the best scientific principles that we have at our disposal.
Daniel Zeichner
Q
Professor Dunwell: I think this comes back to our understanding of genomes. Some of the wording in here comes out of the discussions that we have had within ACRE and the recognition that, probably 20 or 30 years ago, we assumed that one crop had one genome and that was it, but we now know, because you can sequence genomes very easily and quickly, that in fact there is an enormous underlying diversity of genetic material. The number of genes in one variety of maize or corn is different from the number of genes in another. There are also structural rearrangements. You can have great pieces of chromosomes interchanged or moved; it is still a maize plant. These so-called structural variations are an intrinsic part of plant breeding—and also animal breeding. The more we see the diversity of this variation, the more we pick up the fact that many, many plants have DNA that has come from other organisms throughout their evolution; it is the same with animals. Plants have segments of DNA from, say, virus infections hundreds or thousands of years ago perhaps. They have been incorporated into the genome and so, in old-fashioned definitions of GM, those organisms would be considered genetically modified organisms, because they have material from another organism in them. But we accept now that that is the baseline—that many, many organisms have small parts of DNA from many, many organisms. We have nematodes that have plant DNA. We have insects that have plant DNA. These have been moved around during evolution. They do not change the purity of the species. In evolutionary terms, they create the diversity that enables evolution to take place.
That is the background in which the term “natural transformation” has been created. The simple presence of a small fragment or a bit of DNA from another species, which might have been there anyway, is not something that has any impact on hazard or risk.
Soft Plastic Recycling: South Gloucestershire
Jo Churchill Excerpts(2 years, 5 months ago)
Commons ChamberRead Full debate Read Hansard Text Read Debate Ministerial Extracts
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
I thank my hon. Friend the Member for Thornbury and Yate (Luke Hall) for securing this debate on the important issue of soft plastic recycling—he was ably aided by my right hon. Friend the Member for Kingswood (Chris Skidmore) in pointing out how important this is—and I begin by saying what a champion he is on this issue. He knows that the Government are committed to tackling plastic pollution. As he outlined, we have a range of ambitious policies to do so. Plastic film makes up a third of all plastic packaging placed on the market, so driving better recycling is particularly important.
Plastics often get a bad name, but they are incredibly important and useful because their strength and versatility make them a very valuable material in many areas of life. For example, the plastic packaging that challenges us when we try to get rid of it also preserves our food and plays a key part in extending the shelf life of some items and in reducing food waste. However, plastics cause problems when they leak out of the system into the environment. As my hon. Friend said, they can pollute our waterways and oceans and harm our wildlife.
The ban on microbeads—which my hon. Friend referred to—in rinse-off personal care products will help to stop billions of tiny pieces of plastic potentially entering the aquatic environment every year. We are reforming the waste system to ensure that we reduce, reuse and recycle plastic. By ensuring that more plastic is recycled, we will cut the amount of that valuable resource that is sent to landfill. We can also achieve carbon savings from reducing the amount of plastic waste that is sent to incineration. Arguably, the driver there is to reduce that consumption.
On consistency in recycling—my hon. Friend mentioned the different streams—through our landmark Environment Act 2021, which the House passed last November, we will ensure that all homes and businesses get the proper recycling service to which he referred. That will ensure that the same set of materials are collected across England, making it easier for our councils to deliver and making it clearer to the public what they can and cannot recycle. He spoke about our working together and, arguably, that will make it much easier from the get-go. Plastic film makes up a third of all plastic packaging on the market, yet, as my hon. Friend mentioned, only about a fifth of local authorities in England—17%—currently collect plastic film. Just 5% of plastic film put on the market is recycled. That is a woeful figure that we need to drive up.
My right hon. Friend the Member for Kingswood said that we need to be ambitious. I assure him that we intend to be ambitious. We recognise that there are challenges with the collection and sorting of material, but doing more is absolutely at our heart. We have received a clear message from industry that it requires early signalling of the intent to require the collection of plastic film and flexible packaging for recycling to stimulate the necessary investment needed to improve infrastructure. My hon. Friend the Member for Thornbury and Yate is right that it is better in some parts of the country than in others.
To provide that early signal, in our recently published consultation on extended producer responsibility for packaging, we announced that plastic film would be collected from every home and business in the UK by 2027, so the starting gun has been fired. Including plastic film and flexible packaging in kerbside collections will make things much easier and much more convenient for our householders and businesses. Until then, supermarkets and others in the private sector are performing a key role by providing further opportunities for in-store collection of plastic film for recycling. My hon. Friend mentioned one or two companies that are really beginning to push for suitable and sufficient facilities, very often because customers are demanding it.
I appreciate my hon. Friend’s point about access to wider retailer collection schemes for soft plastics. I agree that a wider-ranging initiative such as kerbside collections is needed to ensure that people in rural as well as urban areas are able to access facilities and recycle their soft plastics.
I thank my hon. Friend for his interest in the collection and packaging reforms. We will publish a response to the consultations on consistency and the deposit return scheme shortly. We received a wide range of views from stakeholders. Building a large, complex system obviously takes time, but we want to make sure that we get it right.
Extended producer responsibility for packaging ensures that packaging producers, not the taxpayer, cover the cost of disposing of packaging that they put on the market, powerfully encouraging them, along with the plastic packaging tax, to make their products easier to recycle. Under extended producer responsibility, we are introducing modulated fees to drive producers to make more sustainable packaging designs. This will help to reduce unnecessary plastic packaging and incentivise the use of recyclable materials.
The Government have also invested £20 million into four new facilities to support the development of new plastic waste recycling technologies. We expect that private investment will continue and increase as we move towards legislating on the requirement to collect plastic film from households and businesses.
To support our ambitious goals to recycle plastic film, the Department for Environment, Food and Rural Affairs, alongside the Flexible Plastic Fund, UK Research and Innovation and Zero Waste Scotland, is funding a multimillion-pound pilot project on flexible plastic kerbside collections. The FlexCollect project, launched in May, will provide financial support for selected local authorities to roll out kerbside collections in trials over a three-year period. Insights from the project will be invaluable in informing how councils can best collect plastic film.
I encourage all councils to express their interest in the project. To ensure that the project is as beneficial as possible in informing the roll-out of plastic film collections on a national level, it will need a good cross-section of local authorities to make it a success. We need to understand the challenges and successes in rolling it out to all households and businesses so that people are able to recycle their plastic film, whether they are in a rural location or in the centre of a city. The selection process will help to identify whether local authorities are a good fit for the project and due diligence will be applied. Appropriate governance structures are in place to ensure that the selection process is fair and transparent; I am sure that my hon. Friend agrees and approves.
The project is being managed by a consortium of organisations including: Ecosurety, SUEZ Recycling and Recovery UK Ltd, RECOUP and WRAP, the Waste and Resources Action Programme. A cross-section of industry stakeholders including the Local Authority Recycling Advisory Committee, the National Association of Waste Disposal Officers, the Chartered Institution of Wastes Management and the Environmental Services Association are also involved to ensure all parts of the value chain involved in the collection and recycling of this material are considered. I understand that announcements will be made about participation in the Flexible Plastic Fund’s FlexCollect project over the next few months. I am truly delighted that South Gloucestershire Council has submitted a bid for FlexCollect. I am sure that it will be carefully considered, and, like my hon. Friend, I pay tribute to all those who work in the refuse and recycling sector. It is great to see councils such as his driving progress in recycling, and challenging themselves to do better and do more for their residents.
I thank my hon. Friend again for initiating the debate. I know that he is a tireless champion for the environment as well as the people of Thornbury and Yate, and that he builds on the excellent work of South Gloucestershire Council across a range of areas. The Government are committed to leaving our environment in a better state than the one in which we found it, and fighting plastic pollution and providing easy systems for our residents and businesses are a key part of that legacy.
Question put and agreed to.
Oral Answers to Questions
Jo Churchill Excerpts(2 years, 6 months ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Chris Green (Bolton West) (Con)
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
The Department for Environment, Food and Rural Affairs has one of the five largest science and innovation budgets in Government. It is investing £270 million in innovation through the farming innovation programme to 2029, working with our leading-edge agricultural research institutions across the UK’s four nations to harness the power of innovation.
Chris Green
The advocate-general of the European Union recommended gene editing, but the European Court of Justice opposed it and put it in the same category as genetically modified organisms. Professor Nigel Halford said that
“the decision could set back agbiotech in Europe by another 20 years. We are already a generation behind. Young scientists interested in agbiotech are likely to move to places where common sense and scientific evidence prevail”.
In the name of better productivity, healthier food and scientific progress, when does my hon. Friend expect to see gene-edited crops on the UK market?
Jo Churchill
The EU has just opened a consultation on the issue, because my hon. Friend is totally right that precision-bred crops are very different. We have already taken steps, starting with the introduction of the Genetic Technology (Precision Breeding) Bill, which will go into Committee very shortly. Through its agricultural research institutes, the UK is at the leading edge. There will be overwhelming benefits for climate change, food resilience, pest resistance and so on. I look forward to the Bill receiving support across the House, going through Committee and going on to the other place.
Fleur Anderson (Putney) (Lab)
Margaret Greenwood (Wirral West) (Lab)
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
We are clear that we meet all the requirements to gain both part 1 listed status and recognition of the UK’s tapeworm-free status. We see no valid animal health reason for those not to be granted. We are carrying out further engagement to make progress on this issue.
Margaret Greenwood
I thank the Minister for her answer and wonder whether she could elaborate. My constituent, Stephen, who is blind and partially deaf, has an assistance dog called Jodie. Steven has told me that he is required to pay £160 for an animal health certificate and vaccines each time he takes Jodie to an EU country. I wrote to DEFRA on Steven’s behalf more than a year ago and received a response that basically said that the change has still not happened. Does the Minister recognise the impact of this slow progress on Stephen and other people who rely on assistance dogs? Could she elaborate further on what Stephen might do?
Jo Churchill
I do recognise the challenge. There is no change for animals coming from the EU to here and there is no reason why that arrangement should not be reciprocal. We are proactively engaging with the assistance dog community and relevant stakeholders and we are continuing the engagement with the EU to make sure that we can overcome this challenge.
Jessica Morden (Newport East) (Lab)
Tom Randall (Gedling) (Con)
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
As my right hon. Friend the Secretary of State has highlighted, we have witnessed the worst avian flu outbreaks on record in recent months, having sustained 122 cases this year. We will lift restrictions in disease control zones, including those on racing pigeons, as soon as we are able to do so, because of the biosecurity need. This week, we have announced that scientists across the UK will join forces in a major new research consortium to fight against avian flu. I note that my hon. Friend has written to me, so he will get a fuller answer.
Chris Stephens (Glasgow South West) (SNP)
Mohammad Yasin (Bedford) (Lab)
Jo Churchill
I am very much looking forward to visiting next Monday, and I reassure the hon. Member that while there is no silver bullet, it is important that we use everything we have available. The innovation that is coming in vertical farms, in greenhouses and so on gives us the opportunity to produce more food in the UK to feed ourselves.
David Simmonds (Ruislip, Northwood and Pinner) (Con)
Genetic Technology (Precision Breeding) Bill
Jo Churchill ExcerptsWednesday 15th June 2022
(2 years, 6 months ago)
Commons ChamberRead Full debate Genetic Technology (Precision Breeding) Act 2023 View all Genetic Technology (Precision Breeding) Act 2023 Debates Read Hansard Text Read Debate Ministerial Extracts
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
I thank all hon. Members for their contributions, particularly my hon. Friends the Members for South Ribble (Katherine Fletcher), for York Outer (Julian Sturdy), for South Cambridgeshire (Anthony Browne), for North West Norfolk (James Wild) and for Banff and Buchan (David Duguid). I also thank the hon. Member for North Shropshire (Helen Morgan) and the Opposition for the constructive way they have leaned into this debate today. I would immediately say, “Yes, we need to work together on this.” I think the majority of those in this House see the huge opportunity we have here.
“The emergence of genome editing is a significant moment, as it represents a possible step change in introducing a new generation of potentially transformative biotechnologies into the food and farming system.”
Those are not my words; they are from the Nuffield report.
Ruth Edwards (Rushcliffe) (Con)
I welcome this Bill, which will hugely enhance our future food security. May I draw the Minister’s attention to pioneering new genetic editing techniques being developed at the University of Nottingham’s Sutton Bonington campus, and invite her to join me on a visit there to see that groundbreaking research in action?
Jo Churchill
I thank my hon. Friend very much. I believe my hon. Friend the Member for South Ribble is an alumna of that august institution, as indeed am I, so I would be delighted to visit it. That intervention raises a key point that, because of the limited time, I will address in a general sense.
We do have some of the finest institutions, and many of them are lodged in Scotland. The James Hutton Institute and the Roslin Institute are beyond good in this space. They need to be supported. They do not need to wait for others to follow. Our door is open. We want to get this right. We want to work with the hon. Member for Edinburgh North and Leith (Deidre Brock). Professor Colin Campbell of the James Hutton Institute has said that it is right. Professor Helen Sang from the Roslin Institute has given evidence to say that this is what we need. She is working on ensuring that we can beat avian flu, which attacks both animals kept inside barns and those kept outside.
We have the opportunity to improve animal welfare here, and I would like to address that point full on. Animal welfare is currently of a high standard in this country, and it is not true to say that this Bill will affect it. Our animals are protected by comprehensive and robust animal health welfare legislation, including the Animal Welfare Act 2006 and the Welfare of Farmed Animals (England) Regulations 2007, passed by Labour. These provisions help to reinforce the fact that the welfare of animals is a key priority, and it is simply not true to say that the Bill will lead to a diminution in those standards.
The Bill allows us to take the opportunities that have been presented to us through leaving the European Union. It is important to celebrate our country’s strengths at Rothamsted, James Hutton, John Innes and Roslin, all of which I have visited, and I hope to go to Aberystwyth soon. It is important that we move on this as a country. By encouraging greater research and development in the use of precision-breeding technologies, we are supporting that drive. Innovation is key to enhancing the sustainability and resilience of our agricultural systems by harnessing the benefits of precision breeding to eradicate disease, as we have discussed.
My hon. Friend the Member for North West Norfolk (James Wild) and my hon. Friend the Member for York Outer addressed the issue of section 3. The Bill provides the Food Standards Agency with an opportunity to build from scratch a tailor-made framework that is proportionate for the UK. This will allow swifter progress for businesses wishing to market precision-bred organisms while still ensuring the safety of our food.
I could not agree more that safety, transparency, proportionality, traceability and customer confidence is what we are building here. The EU is currently reviewing its systems and has acknowledged that its current system is not fit for purpose. I would indeed be happy to share that documentation, which is publicly available, with the hon. Member for Edinburgh North and Leith. It is important that we move ahead in this area, and our scientists, farmers and researchers all want us to do it. It is simply not true to say that this will allow multinationals and conglomerates to drive forward in this space. Actually, in the countries that have already driven PBOs into their system, we see democratisation, with a greater proportion of precision breeding patents being held by smaller and local businesses.
In response to the hon. Member for Cambridge (Daniel Zeichner) and the hon. Member for Brighton, Pavilion (Caroline Lucas), who is no longer in her place, I agree that food security is a top priority. We have taken account of the Nuffield report and public concerns, and we are constantly in dialogue with our stakeholders. On Monday, we met animal welfare stakeholders to talk about the declaration and how they can feed into that. I agree that consumers need clear labelling, but the FSA will authorise products for sale only if they present no risk to health and do not mislead customers.
As this technology brings no safety risk, labelling will not be required to indicate the methods used in breeding. It is unnecessary because, as has been repeatedly pointed out, it is the same as traditional breeding. The countries that are already in this space—Canada, Japan, the United States, Brazil and Argentina—do not do that. A public register will be available on gov.uk to ensure further traceability.
There is a great deal more that I could go into on the particular things that were brought up, but I want to finish by saying that this is a huge area of advantage. We need to go forward as a country making sure that we take our scientists with us, enhance our research and breeding practices, and enable consumer confidence. Ultimately the key aim of the Bill is to ensure that precision-bred plants, animals, food and feed products are regulated proportionately to their risk so that we can fully embrace the benefits and advantages of scientific progress that has been made over the past 30 years. The Bill is good news, and I commend it to the House.
Question put and agreed to.
Bill accordingly read a Second time.
Breed-specific Legislation
Jo Churchill Excerpts(2 years, 6 months ago)
Westminster HallRead Full debate Read Hansard Text Read Debate Ministerial Extracts
Westminster Hall is an alternative Chamber for MPs to hold debates, named after the adjoining Westminster Hall.
Each debate is chaired by an MP from the Panel of Chairs, rather than the Speaker or Deputy Speaker. A Government Minister will give the final speech, and no votes may be called on the debate topic.
This information is provided by Parallel Parliament and does not comprise part of the offical record
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
It is a pleasure to serve under your chairmanship, Sir George. I thank the hon. Member for Neath (Christina Rees) for introducing the debate and all hon. Members for their contributions, which have all been extremely well thought out and articulated, and have highlighted the pain for animals and owners on both sides of the equation. The hon. Member for Chesterfield (Mr Perkins) highlighted eloquently how we value our pets, but also how that cannot be at the expense of ensuring that safety is paramount in our minds.
I hope today to give a little encouragement about how we are already on the way to some of the things to which hon. Members have referred, but I would be the first to say that we are still gathering the evidence. That is important, because we work with many of the partners mentioned today, whether that be academics and the veterinary profession, or our police, local authorities and other stakeholders. They are all key to ensuring that we have the right evidence base with which to move forward.
Dr Neil Hudson (Penrith and The Border) (Con)
I am encouraged to hear that the Government’s response is to look at the evidence when reviewing such legislation. It is a sensitive area that people feel passionately about, and we have heard some powerful interventions and speeches today. Sadly, some dogs and some behaviours are dangerous to people and to animals, as we heard. In combination with powerful jaw structures and dog bodies, that becomes quite frightening. Some, including the hon. Member for Newport West (Ruth Jones), talk about how we should be looking at the deed, not the breed, and I am sympathetic to that. However, as we know, some breeds are dangerous, and I suggest to the Minister that a middle ground might be to think holistically and to consider breed and/or deed.
Jo Churchill
My hon. Friend speaks both as a Member in this place and as an esteemed member of the veterinary profession, pointing out that we are not looking for an all-or-nothing approach here. That is very timely, and I thank him for it.
Sadly, we have seen a number of tragic fatalities from dog attacks in recent months. Many of them have involved children, but not exclusively so. The Government are already taking action to address that. I will set out what we are doing, working with the other stakeholders that I mentioned. Indeed, I was heartened that the hon. Member for Neath referenced how some of the work is beginning to get under way.
We have been working with stakeholders, including the police, local authorities and—a couple of hon. Members asked about this—the devolved Administrations, in order to develop simple key messages to promote safer interactions, in particular between children and dogs. The dog safety code launched last week highlights three key messages to all dog owners and families with children. As the hon. Member for Chesterfield said, and as we know in our home, a family pet is a great asset but has its own needs, and those needs have to be cared for. Dog owners should be alert and always keep an eye on their dog when it is around children. They should not leave them alone together. They should be aware and get to know their dog—dogs use signals to tell us when they are stressed. Be safe, because any dog can bite and accidents happen very swiftly.
Today is the start of Child Safety Week, and the Department of Health and Social Care and the Department for Education are sharing that messaging, which will also be used by health visitors and child safeguarding professionals. We will continue that over the summer holidays, because we want the dog safety code to be embedded in future communications. At this point, I put on the record my thanks to Marisa Heath of the Canine and Feline Sector Group for her support in co-ordinating that work. As many have said today, others helping to get this right is what we need.
Members are well aware of the work that we commissioned from Middlesex University to explore measures to reduce dog attacks and to promote responsible ownership across all breeds of dog. We published that report in December last year, and in response to it we established the responsible dog ownership project with the police, local authorities and animal welfare stakeholders, to consider the report’s recommendations in detail, build on the evidence base and provide advice to the Government.
Four areas are examined, and I will go into some of the specifics, in particular to answer some of the questions of the hon. Member for Neath, although many Members present brought up areas such as enforcement. The project is looking at strengthening enforcement; developing and supporting education initiatives, which is seen as key; improving the quality and accessibility of dog training; and—I think this was brought up by virtually every Member who spoke, but certainly by the hon. Members for Neath and for Rutherglen and Hamilton West (Margaret Ferrier), and my hon. Friend the Member for Southend West (Anna Firth)—the importance of data collection right across the system, whether by hospitals when there have been attacks, veterinarians or the police, so that we know what we are dealing with. We expect that project to conclude its work in early 2023. The Government will then consider the advice and work through the next steps.
To address the point about breed-specific legislation not working, repealing the breed-specific provisions without other changes would not help public safety. That is why we are working on ensuring we have the right evidence base. We are not willing to repeal the breed-specific provisions contained in the Dangerous Dogs Act without other changes being made. We need to walk carefully through these things and make sure that we reach the right conclusions.
The hon. Member for Neath talked about rehoming exempted dogs. Current legislation only permits the transfer of keepership of prohibited dogs when the existing keeper has died or is seriously ill. Case law has also confirmed that a person with a pre-existing relationship with the dog can apply to place it on the index, even if they are not the owner or the most recent keeper.
The hon. Lady also raised the issue of putting down good-natured dogs. Any changes relating to rehoming must consider the signals that sends about the acceptability of keeping those types of dogs. We must ensure that we draw the right balance and find the middle ground so that legislation is both workable and enforceable, and cares for the animal in the best possible way.
Several hon. Members spoke about why the data is lacking. The report by Middlesex University highlighted that much more could be done about the recording of dog attacks. As I have said, we are working with the institutions I mentioned, as well as NHS Digital, to make sure we get that data in a timely way.
On the question of how we address dog attacks by other breeds, section 3 of the Dangerous Dogs Act makes it an offence to allow a dog of any breed or type to be “dangerously out of control” in any place. In addition, the Anti-Social Behaviour, Crime and Policing Act 2014 includes specific measures to enable the police and local authorities to tackle irresponsible dog ownership before a dog attack occurs, including through the use of community protection notices. It is important that we know what legislation we have already, and why it is or is not working.
On dog-on-dog attacks, I extend my enormous sympathy to the constituent of my hon. Friend the Member for Southend West. I have heard my hon. Friend talk about the attack on her constituent’s dog before and it sounded utterly horrific. Existing powers allow dog-on-dog attacks to be tackled, including through issuing community protection notices, as I just mentioned, and through prosecution under the 1991 Act and the Dogs Act 1871. The Animal Welfare (Kept Animals) Bill will bring in new measures to crack down on dog attacks on livestock. We do not want to bring in legislation piecemeal and we want to get it right.
The hon. Member for Neath asked what we can do to look at the time dogs spend in kennels. The interim exemption scheme allows dogs to remain with their owners in advance of a court hearing if the police determine that the dog will not pose a threat to public safety. I assure her that DEFRA officials are working with police forces across the country to increase uptake of the interim exemption scheme. Commercial kennels are required to meet the standards placed upon them and are licensed by the local authority.
The hon. Member for Chesterfield said that dogs should not be judged by their appearance. The Middlesex University report does not go so far as to say that we should move away from breed-specific legislation, but it recognises that a range of factors need to be considered. That is why I hope that when the project comes forward early in 2023 we will have the framework to move forward.
On responsible dog ownership, the report recommended that we look at additional legal requirements on dog ownership, including, as a basic standard, that dog owners must demonstrate a minimum standard of dog knowledge and be on a register attesting to that fact. We are also looking to improve the microchipping regime, because those databases are complex—I think there are 17, and they need to be brought into one place.
Wayne David
Will the Government at least look at the possibility of licensing dogs?
Jo Churchill
When the evidence comes back, we will obviously look at it. We microchip all our dogs, and if a microchipping database works effectively and we have a good education programme, I would argue that that should be sufficient, but we are waiting with an open mind until the evidence comes back.
I understand the strength of feeling about breed-specific legislation, but the Government must balance the views of those who want it repealed with our responsibility to protect the public. We remain concerned that lifting the current restrictions may not be the optimal move forward. However, the responsible dog ownership project will explore these issues more widely, and if we make any changes, we will ensure that public safety remains the absolutely paramount point at the heart of the regime.
I hope that colleagues are reassured that we take this important subject seriously. I look forward to carrying on the collegiate conversation with them to ensure we get this right.
Deposit Return Scheme
Jo Churchill Excerpts(2 years, 6 months ago)
Commons ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
The Parliamentary Under-Secretary of State for Environment, Food and Rural Affairs (Jo Churchill)
If you will indulge me, Mr Deputy Speaker, on the day of the Humble Address to Her Majesty, I wish to add my voice and those of the constituents of Bury St Edmunds to the voices of others in this place who have expressed their deep appreciation of and thanks for Her Majesty’s dedication, kindness, good humour and service to our nation. She has visited our great county on many occasions and I know that we will celebrate, as the rest of the country will, with bunting and fanfare over the coming week. I am looking forward to judging a fancy dress competition in one of my lovely villages.
As a long-term advocate for our natural environment, Her Majesty, I am sure, would be extremely interested in the important subject that we are discussing today. On that note, I thank my hon. Friend the Member for Kettering (Mr Hollobone) for securing this debate and for the opportunity to discuss the Government’s plans for introducing a deposit return scheme for drinks containers.
As I am sure my hon. Friend is aware, there is an awful lot going on in this space, driven by our resources and waste strategy and the powers that we took in the Environment Act 2021, which was passed last November. With that in mind, we are proud to be driving forward work across the collection and packaging reforms, which is made up of the deposit return scheme, the extended producer responsibility for packaging and the increased consistency in recycling collections in England to which he referred.
The DRS is pivotal to this Government’s commitment to increasing recycling rates. However, we should not overlook that it will provide other benefits. In particular, it will deliver high-quality recyclate for recycling; enable the drinks industry to close the loop on its packaging; help move the UK towards the circular economy, where resources are kept in use longer and waste is minimised, taking us away from that linear throwaway society; deter the littering of in-scope containers; reduce the associated damage to wildlife and habitats; and therefore promote pro-environmental consumer behaviours, with potential knock-on effects on other positive environmental activities.
My hon. Friend has raised some important concerns on behalf of the industry. I want to be clear that our ambition is to introduce a deposit return scheme that works for everyone—for the consumer and across the industries. I know that, in many of our households, across the UK, drinks packaged in metal cans are drunk regularly. For that reason, we all recognise that those cans—light, sturdy, and convenient for storage and transport—have intrinsic qualities that will always make them desirable to consumers and the product of choice. We are of course mindful that any cost to people’s purses, or businesses is particularly tough in the current environment, but we do want to introduce policies that encourage recycling and reduce the amount of litter that blights our environment.
Although DRS is a complex policy to introduce, requiring the efforts of multiple industries, in one way, we are lucky. As my hon. Friend said, there are 40 other deposit return schemes out there, in other nations, from which we can learn. Not only are we drawing on the experiences of the roll-out of DRS in Scotland to inform implementation and planning, but I had the pleasure of meeting the Environment Minister from Lithuania, where a scheme was also recently introduced. I have plans to visit Norway shortly to find out more about its deposit return scheme. Norway has not included glass in its scheme, and nor have the Netherlands or Sweden. I note that the hon. Member for Strangford (Jim Shannon) is no longer in his place, but I understand that southern Ireland, in its plans for a scheme, is contemplating excluding glass. There is, therefore, a mixture of schemes out there.
I recognise that there are deposit return schemes with different scope across the United Kingdom, given that glass is excluded in England and Northern Ireland, but we remain totally committed to working with the devolved Administrations to ensure that there is a completely coherent, interoperable system across the UK.
Excluding glass offers us an opportunity to look at how we incentivise reusable schemes for glass. Those containers that are not within the deposit return scheme are within the extended producer responsibility scheme, so exclusion does not in any way mean that we are not making policy to improve the reuse, recycling and resource efficiency of those things. On the question of VAT, as my hon. Friend would expect, we are in discussion with Her Majesty’s Treasury. I have met the Financial Secretary on this matter in the recent past, as has the Secretary of State.
Ultimately, DEFRA’s ambitious collections and packaging reform agenda cannot be delivered by Government alone. The deposit return scheme will be an industry-led scheme. For that reason we, alongside colleagues in the devolved Administrations, continue to work closely with all relevant sectors to implement a scheme that is as coherent and aligned as we can make it.
I take this opportunity to thank all those who have fed into the consultations, and those who continue to be generous with their insights and expertise into what is positive about schemes they run and where they think we can improve. That will ensure that we deliver a successful deposit return scheme in England.
Mr Deputy Speaker (Mr Nigel Evans)
Before I put the Question, on behalf of the Speaker and the Deputy Speaker team, I wish everybody working at the Palace of Westminster a most glorious, historic platinum jubilee four-day celebration next week.
Question put and agreed to.